Use: Labeled indications
- Acute bacterial exacerbations of chronic bronchitis in adults
- Acute bacterial sinusitis in adults
- Uncomplicated skin and skin structure infections in adults
- Urethritis and cervicitis in adults
- Genital ulcer disease in men
- Acute otitis media in pediatric patients (6 months of age and older)
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ZITHROMAX is a macrolide antibacterial drug indicated for treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:
- Acute bacterial exacerbations of chronic bronchitis in adults (1.1)
- Acute bacterial sinusitis in adults (1.1)
- Uncomplicated skin and skin structure infections in adults (1.1)
- Urethritis and cervicitis in adults (1.1)
- Genital ulcer disease in men (1.1)
- Acute otitis media in pediatric patients (6 months of age and older) (1.2)
- Community-acquired pneumonia in adults and pediatric patients (6 months of age and older) (1.1, 1.2)
- Pharyngitis/tonsillitis in adults and pediatric patients (2 years of age and older) (1.1, 1.2) Limitation of Use: ZITHROMAX is not recommended in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors. (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX and other antibacterial drugs, ZITHROMAX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.4) 1.1 Indications in Adult Patients ZITHROMAX is indicated in adult patients for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:
- Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.
- Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae.
- Community‑acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy.
- Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first‑line therapy in individuals who cannot use first‑line therapy.
- Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae.
- Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae.
- Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Indications in Pediatric Patients ZITHROMAX is indicated in pediatric patients for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: [see Use in Specific Populations (8.4) and Clinical Studies (14.2)].
- Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae, in pediatric patients 6 months of age and older.
- Community‑acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in pediatric patients 6 months of age and older appropriate for oral therapy.
- Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy in pediatric patients 2 years of age and older. 1.3 Limitations of Use Azithromycin is not recommended in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following:
- patients with cystic fibrosis,
- patients with nosocomial infections,
- patients with known or suspected bacteremia,
- patients requiring hospitalization,
- elderly or debilitated patients, or
- patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX and other antibacterial drugs, ZITHROMAX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
- Hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide
- History of cholestatic jaundice or hepatic dysfunction with azithromycin
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS • Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. (4.1) • Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. (4.2) 4.1 Hypersensitivity ZITHROMAX is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. 4.2 Hepatic Dysfunction ZITHROMAX is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin.
Dosing: Adult
- Community-acquired pneumonia (mild); pharyngitis (second line); uncomplicated skin infection: 500 mg on day 1, then 250 mg daily on days 2 to 5
- Acute bacterial exacerbation of COPD: 500 mg day 1 then 250 mg days 2–5, or 500 mg daily for 3 days
- Acute bacterial sinusitis: 500 mg daily for 3 days
- Non-gonococcal urethritis and cervicitis; chancroid: 1 g once
- Gonococcal urethritis and cervicitis: 2 g once
- Recommended Dosage for Adult Patients (2.1)
- Infection Recommended Dose/Duration of Therapy Community-acquired pneumonia (mild severity) Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5. Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days. Acute bacterial sinusitis 500 mg once daily for 3 days. Genital ulcer disease (chancroid) Non-gonococcal urethritis and cervicitis One single 1 gram dose. Gonococcal urethritis and cervicitis One single 2 gram dose. Recommended Dosage for Pediatric Patients (2.2)
- Infection Recommended Dose/Duration of Therapy Acute otitis media (6 months of age and older) 30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg/day on Days 2 through 5. Acute bacterial sinusitis (6 months of age and older) 10 mg/kg once daily for 3 days. Community-acquired pneumonia (6 months of age and older) 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg once daily on Days 2 through 5. Pharyngitis/tonsillitis (2 years of age and older) 12 mg/kg once daily for 5 days.
2.1 Recommended Dosage for Adult Patients
2.1 Recommended Dosage for Adult Patients Recommended dosages and durations of therapy in adult patient populations vary by indications [see Indications and Usage (1.1) and Clinical Pharmacology (12.3)]. ZITHROMAX tablets and ZITHROMAX for oral suspension can be taken with or without food. Table 1. Recommended dosage for Adult Patients by Indication Infection Due to the indicated microorganisms [see Indications and Usage (1.1)].
Recommended Dose/Duration of Therapy Community-acquired pneumonia Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial exacerbations of chronic obstructive pulmonary disease 500 mg once daily for 3 days OR 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial sinusitis 500 mg once daily for 3 days Genital ulcer disease (chancroid) One single 1 gram dose Non-gonococcal urethritis and cervicitis One single 1 gram dose Gonococcal urethritis and cervicitis One single 2 gram dose
2.2 Recommended Dosage for Pediatric Patients
2.2 Recommended Dosage for Pediatric Patients Recommended dosages and durations of therapy in pediatric patient populations vary by indications [see Indications and Usage (1.2) and Clinical Pharmacology (12.3)]. ZITHROMAX for oral suspension can be taken with or without food. Table 2. Recommended dose for Pediatric Patients by Indication Infection Due to the indicated microorganisms [see Indications and Usage (1.2) and Use in Specific Populations (8.4)].
Recommended Dose/Duration of Therapy see dosing tables below for maximum doses evaluated by indication. Acute otitis media 30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg/day on Days 2 through 5. Acute bacterial sinusitis 10 mg/kg once daily for 3 days.
Community-acquired pneumonia 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg once daily on Days 2 through 5. Pharyngitis/tonsillitis 12 mg/kg once daily for 5 days. PEDIATRIC DOSAGE GUIDELINES FOR OTITIS MEDIA, ACUTE BACTERIAL SINUSITIS, AND COMMUNITY-ACQUIRED PNEUMONIA (Age 6 months and above, [see Use in Specific Populations (8.4)]) Based on Body Weight Table 3.
Otitis Media and Community-Acquired Pneumonia: (5-Day Regimen) Effectiveness of the 3-day or 1-day regimen in pediatric patients with community-acquired pneumonia has not been established [see Use in Specific Populations (8.4)]. Dosing Calculated on 10 mg/kg/day Day 1 and 5 mg/kg/day Days 2 to 5. Weight 100 mg/5 mL 200 mg/5 mL Total mL per Treatment Course Total mg per Treatment Course Kg Day 1 Days 2-5 Day 1 Days 2-5 5 2.5 mL; (½ tsp) 1.25 mL; (¼ tsp) 7.5 mL 150 mg 10 5 mL; (1 tsp) 2.5 mL; (½ tsp) 15 mL 300 mg 20 5 mL; (1 tsp) 2.5 mL; (½ tsp) 15 mL 600 mg 30 7.5 mL; (1½ tsp) 3.75 mL; (¾ tsp) 22.5 mL 900 mg 40 10 mL; (2 tsp) 5 mL; (1 tsp) 30 mL 1200 mg 50 and above 12.5 mL; (2½ tsp) 6.25 mL; (1¼ tsp) 37.5 mL 1500 mg Table 4.
Otitis Media and Acute Bacterial Sinusitis: (3-Day Regimen) Effectiveness of the 5-day or 1-day regimen in pediatric patients with acute bacterial sinusitis has not been established [see Use in Specific Populations (8.4)]. Dosing Calculated on 10 mg/kg/day. Weight 100 mg/5 mL 200 mg/5 mL Total mL per Treatment Course Total mg per Treatment Course Kg Days 1-3 Days 1-3 5 2.5 mL; (1/2 tsp) 7.5 mL 150 mg 10 5 mL; (1 tsp) 15 mL 300 mg 20 5 mL (1 tsp) 15 mL 600 mg 30 7.5 mL (1½ tsp) 22.5 mL 900 mg 40 10 mL (2 tsp) 30 mL 1200 mg 50 and above 12.5 mL (2 ½ tsp) 37.5 mL 1500 mg Table 5.
Otitis Media: (Single-dose Regimen)* Dosing Calculated on 30 mg/kg as a single dose. Weight 200 mg/5 mL Total mL per Treatment Course Total mg per Treatment Course Kg 1-Day Regimen 5 3.75 mL;(3/4 tsp) 3.75 mL 150 mg 10 7.5 mL;(1½ tsp) 7.5 mL 300 mg 20 15 mL;(3 tsp) 15 mL 600 mg 30 22.5 mL;(4½ tsp) 22.5 mL 900 mg 40 30 mL;(6 tsp) 30 mL 1200 mg 50 and above 37.5 mL;(7½ tsp) 37.5 mL 1500 mg The safety of re-dosing azithromycin in pediatric patients who vomit after receiving 30 mg/kg as a single dose has not been established.
In clinical studies involving 487 patients with acute otitis media given a single 30 mg/kg dose of azithromycin, 8 patients who vomited within 30 minutes of dosing were re-dosed at the same total dose.
2.3 Pediatric Dosage Guidelines for Pharyngitis/Tonsillitis
2.3 Pediatric Dosage Guidelines for Pharyngitis/Tonsillitis The recommended dose of ZITHROMAX for pediatric patients 2 years of age and older with pharyngitis/tonsillitis is 12 mg/kg once daily for 5 days [see Use in Specific Populations (8.4)] PEDIATRIC DOSAGE GUIDELINES FOR PHARYNGITIS/TONSILLITIS (Age 2 years and above, [see Use in Specific Populations (8.4)]) Based on Body Weight Table 6. Pharyngitis/Tonsillitis: (5-Day Regimen) Dosing Calculated on 12 mg/kg/day for 5 days.
Weight 200 mg/5 mL Total mL per Treatment Course Total mg per Treatment Course Kg Day 1-5 8 2.5 mL; (½ tsp) 12.5 mL 500 mg 17 5 mL; (1 tsp) 25 mL 1000 mg 25 7.5 mL; (1½ tsp) 37.5 mL 1500 mg 33 10 mL; (2 tsp) 50 mL 2000 mg 40 12.5 mL; (2½ tsp) 62.5 mL 2500 mg
2.4 Preparation Instructions
2.4 Preparation Instructions for ZITHROMAX for Oral Suspension Constituting instructions for ZITHROMAX for Oral Suspension 300, 600, 900, 1200 mg bottles are described in table 7 below. Table 7. Preparation of Zithromax for Oral Suspension: Volume of Water to add, Total Volume and Azithromycin Concentration After Constitution Volume of water to be added Total volume after constitution (azithromycin content) Azithromycin concentration after constitution 9 mL (300 mg) 15 mL (300 mg) 100 mg/5 mL 9 mL (600 mg) 15 mL (600 mg) 200 mg/5 mL 12 mL (900 mg) 22.5 mL (900 mg) 200 mg/5 mL 15 mL (1200 mg) 30 mL (1200 mg) 200 mg/5 mL Shake well before each use.
Oversized bottle provides shake space. Keep tightly closed. After mixing, store constituted ZITHROMAX for oral suspension at 5° to 30°C (41° to 86°F) and use within 10 days. Discard after full dosing is completed.
Dosing: Altered kidney function
Azithromycin is eliminated mainly in bile; about 6% appears unchanged in urine. In the US label's kidney study, exposure was nearly unchanged at a GFR of 10–80 mL/min, and peak level and AUC rose 61% and 35% below 10. The label gives no kidney dose change.
Kidney function measure: Label PK study uses GFR (mL/min); no dose bands. Shown in the CrCl band rows.
Show full dosing details
- CrCl ≥60 mL/min
- No dose change stated (label). Exposure barely changes at GFR 10–80 (AUC +4%).
- CrCl 30–59 mL/min
- No dose change stated (label). Exposure barely changes at GFR 10–80 (AUC +4%).
- CrCl 15–29 mL/min
- No dose change stated (label). Exposure barely changes at GFR 10–80 (AUC +4%).
- CrCl <15 mL/min (not on dialysis)
- GFR 10–14: as above. Below 10: peak level +61% and AUC +35% (label PK); no dose change stated.
- Hemodialysis (intermittent)
- No dialysis data in label. Specialist input.
- Peritoneal dialysis
- No dialysis data in label. Specialist input.
- CRRT
- Not in label. Li 2020 (Table 3): no change in CVVH, CVVHD or CVVHDF (non-renal elimination).
- Dialyzable? Not stated in label.
- Monitoring QT interval in patients at risk (QT prolongation, low potassium or magnesium, bradycardia, class IA or III antiarrhythmics); liver tests if symptoms; INR with warfarin (label).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- No pediatric kidney dosing in label; the adult label states no dose change.
- eGFR 30–59
- No pediatric kidney dosing in label; the adult label states no dose change.
- eGFR 15–29
- No pediatric kidney dosing in label; the adult label states no dose change.
- eGFR <15 (not on dialysis)
- No pediatric kidney dosing in label; the adult label states no dose change.
- Hemodialysis (intermittent)
- No pediatric dialysis data. Specialist input.
- Peritoneal dialysis
- No pediatric dialysis data. Specialist input.
- CRRT
- No pediatric CRRT data in the cited sources. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
Patients with Renal Impairment Azithromycin pharmacokinetics was investigated in 42 adults (21 to 85 years of age) with varying degrees of renal impairment. Following the oral administration of a single 1.0 g dose of azithromycin (4 × 250 mg capsules), mean C max and AUC 0–120 increased by 5.1% and 4.2%, respectively, in subjects with GFR 10 to 80 mL/min compared to subjects with GFR >80 mL/min. The mean C max and AUC 0–120 increased 61% and 35%, respectively, in subjects with GFR <10 mL/min compared to subjects with GFR >80 mL/min.
Dosing: Pediatric
- Approved ages
- 6 months and older (otitis media, sinusitis); 2 years and older (pharyngitis) (label).
- Usual dose
- Acute otitis media: 30 mg/kg once, or 10 mg/kg daily for 3 days, or 10 mg/kg on day 1 then 5 mg/kg on days 2 to 5. Acute sinusitis: 10 mg/kg daily for 3 days (label).
- Maximum dose
- Adult dose (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use [see Clinical Pharmacology (12.3), Indications and Usage (1.2), and Dosage and Administration (2.2)] Safety and effectiveness in the treatment of pediatric patients with acute otitis media, acute bacterial sinusitis and community-acquired pneumonia under 6 months of age have not been established. Use of ZITHROMAX for the treatment of acute bacterial sinusitis and community-acquired pneumonia in pediatric patients (6 months of age or greater) is supported by adequate and well-controlled trials in adults.
Pharyngitis/Tonsillitis: Safety and effectiveness in the treatment of pediatric patients with pharyngitis/tonsillitis under 2 years of age have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use In multiple-dose clinical trials of oral azithromycin, 9% of patients were at least 65 years of age (458/4949) and 3% of patients (144/4949) were at least 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients. [see Warnings and Precautions (5.4)]
Administration
2.4 Preparation Instructions for ZITHROMAX for Oral Suspension Constituting instructions for ZITHROMAX for Oral Suspension 300, 600, 900, 1200 mg bottles are described in table 7 below. Table 7. Preparation of Zithromax for Oral Suspension: Volume of Water to add, Total Volume and Azithromycin Concentration After Constitution Volume of water to be added Total volume after constitution (azithromycin content) Azithromycin concentration after constitution 9 mL (300 mg) 15 mL (300 mg) 100 mg/5 mL 9 mL (600 mg) 15 mL (600 mg) 200 mg/5 mL 12 mL (900 mg) 22.5 mL (900 mg) 200 mg/5 mL 15 mL (1200 mg) 30 mL (1200 mg) 200 mg/5 mL Shake well before each use. Oversized bottle provides shake space. Keep tightly closed. After mixing, store constituted ZITHROMAX for oral suspension at 5° to 30°C (41° to 86°F) and use within 10 days. Discard after full dosing is completed.
US FDA labelDosage forms
Philippines
- Film-coated tablet: 250 mg, 500 mg
- Powder for oral suspension: 100 mg, 200 mg per 5 mL, 200 mg/5 mL
- Powder for suspension: 200 mg/5 mL
- Tablet: 500 mg
- Suspension: 100 mg/5 mL, 200 mg/5 mL
- Powder for injection: 500 mg
- Lyophilized powder for injection: 500 mg
- Capsule: 250 mg, 500 mg
- Oral suspension: 200 mg/5 mL
- Granule for oral suspension: 200 mg/5 mL
and 14 more forms; see the products table.
Registered products in the Philippines
320 products registered with the Food and Drug Administration (FDA) Philippines list Azithromycin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products320
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AcasiaAzithromycin (as dihydrate) | 500 mg CapsuleAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | CCL Pharmaceuticals (Philippines), Inc.Importer: AMB HK Enterprises Inc. | DRP-7914-06 | Feb 15, 2027 | |
Acce-MacAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Suspension15 mL HDPE White Colored Plastic Bottle with Pilfer Proof Child Resistant Bottle Cap | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Accesspoint International Trading Inc. | DRP-5051 | Jun 10, 2028 | |
Aeromycin - 500Azithromycin (as dihydrate) | 500mg Film - Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DR-XY48943 | Nov 30, 2028 | |
Aeromycin-SAzithromycin (as dihydrate) | 200 mg/5 mL Granules for Oral Suspension15 mL Amber PET Bottle with Plastic Measuring Cup (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Dynasty PharmaceuticalsImporter: Orange Biotec Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3248-11 | Sep 20, 2031 | |
AezithAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's and 30's); Alu/PVC Blister Pack x 3's per Box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Rifemedica CorporationImporter: Pharmakon Biotec Inc. | DRP-5403-03 | Jul 23, 2029 | |
Agycin-500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletIn box of 1-Alu/PVC Blister Pack x 3's | Rx | Bliss GVS Pharma Ltd.India | Bliss GVS Pharma Ltd. | DRP-8333 | Mar 3, 2027 | |
AltozithAzithromycin (as Dihydrate) | 200 mg/5 mL Powder for SuspensionPET Amber Bottle x 15 mL (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Altomed Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-3322-06 | Jul 8, 2029 | |
Altozith-MDAzithromycin (as monohydrate) | 200 mg/5 mL SuspensionAmber Glass Bottle x 30 mL with 10 mL Transparent LDPE Measuring Cup (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Altomed Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3431-10 | Dec 7, 2029 | |
Alzyl 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | Aurobindo Pharma Limited - Unit VIIIndia | AAA Pharma, Inc. | DR-XY47552 | Nov 24, 2026 | |
Alzyl 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | Aurobindo Pharma Limited - Unit VIIIndia | Pharmastar Int'l Trading Corp. | DRP-18228 | Nov 24, 2031 | |
Ambimax ODAzithromycin (as dihydrate) | 100 mg Powder for Oral SuspensionAluminum Blister Pouch (Box of 10's); Aluminum Blister Pouch (Box of 50's) | Rx | Hainan Poly Pharm Co., Ltd.China | Southmed Pharma CorporationImporter: AMB HK Enterprises Inc. | DR-XY42642 | Sep 17, 2029 | |
AMSOMAXAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletALU/ALU BLISTER PACK X 4'S (BOX OF 4'S); ALU/ALU BLISTER PACK X 3'S (BOX OF 3'S) | Rx | CSPC OUYI PHARMACEUTICAL CO., LTD.China | AMSON PHARMACEUTICALSImporter: SAHAR INTERNATIONAL TRADING, INC. | DRP-2644-01 | Nov 9, 2029 | |
AmziproAzithromycin (as dihydrate) | 500 mg CapsuleAlu/Clear PVC Blister Pack x 3's (Box of 1's); Alu/Clear PVC Blister Pack x 4's (Box of 1's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | AMB HK Enterprises, Inc. | DRP-7914 | Feb 15, 2032 | |
Anzal-500Azithromycin (as Dihydrate) | 500 mg TabletAlu/PVC Blister Pack x 3's per box | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-2985 | Jun 16, 2029 | |
Anzal-DSAzithromycin (as dihydrate) | 200 mg/5mL Powder for SuspensionPET Amber Bottle x 15mL (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-3322 | Jul 8, 2029 | |
AthrodimAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension15 mL White coloured HDPE Plastic Bottle with measuring cup in a box Not Applicable | Rx | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Endurance Healthcare Pvt. Ltd. | DRP-6333-01 | Apr 5, 2037 | |
Aza 500Azithromycin | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3’s (Box of 3’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Altomed Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3204-05 | Sep 1, 2029 | |
AzalAzithromycin (as dihydrate) | 500 mg Powder for Injection (IV)10 mL USP Type I Glass Vial + 5 mL FFS Sterile Water for Injection (as Diluent) in a Box | Rx | Gufic Biosciences LimitedIndia | Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4354 | Apr 1, 2028 | |
AzcoreAzithromycin (as dihydrate) | 200 mg/ 5 mL Powder for Oral Suspension32 mL -capacity Amber glass bottle with aluminum cap x 15 mL -net content (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Greencore Pharma Inc.Importer: Triple Tact Import & Export Corp. | DRP-14138-03 | Jun 30, 2028 | |
AzcoreAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Greencore Pharma Inc. | DRP-8640 | Jan 22, 2030 | |
AzcotilAzithromycin (as dihydrate) | 250 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 30's, 100's and 200's) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-4388 | Apr 29, 2028 | |
AzcotilAzithromycin (as dihydrate) | 500mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 2's,12's, 28's, 30's, 100's) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-4391 | Apr 29, 2028 | |
AzeecorAzithromycin | 500 mg Film-Coated TabletPVC/Alu Blister Pack x 3’s Box of 3’s | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | AMK Pharma International TradingImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3204 | Sep 1, 2029 | |
Azeecor 200Azithromycin (as monohydrate) | 200 mg/5 mL SyrupAmber Glass Bottle x 15 mL with 5 mL Transparent LDPE Measuring Cup (Box of 1’s); Amber Glass Bottle x 30 mL with 10 mL Transparent LDPE Measuring Cup (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Speed Cure PharmaImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3431 | Dec 7, 2029 | |
Azeeya-500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 3's (Box of 3's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Aglobal Care, Inc. | DRP-13692 | Apr 13, 2028 | |
AzemaxAzithromycin (as monohydrate) | 200 mg/5 mL Powder Suspensionwith opaque HDPE bottle with LDPE closure and PP measuring cup 30 mL capacity (22.50 mL net content) (Box of 1 bottle) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: The Cathay Drug Company, Inc. | DR-XY45321 | Apr 22, 2031 | |
AzemaxAzithromycin (as monohydrate) | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 3's (Box of 3's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: The Cathay Drug Company, Inc. | DR-XY41106 | Jul 31, 2027 | |
AzemaxAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Umedica Laboratories Pvt. Ltd.India | The Cathay Drug Co., Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-2788-01 | Aug 27, 2031 | |
AzentAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 6’s (Box of 24’s) | Rx | Hizon Laboratories, Inc.Rizal | Pharma Dynamic, Inc. | DRP-3549-02 | Sep 16, 2036 | |
AZERICHAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 3's (Box of 3's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Medirich Pharma Distribution Corp.Importer: AGlobal Care Inc. | DRP-13692-02 | Apr 13, 2028 | |
Azi-200Azithromycin (as monohydrate) | 200 mg/5 mL Powder for SuspensionHDPE White Opaque Plastic Bottle x 22.5 mL with measuring cup (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-15628 | Mar 13, 2030 | |
Azi-500Azithromycin (as monohydrate) | 500 mg Film-Coated TabletAlu/White PVC Blister Pack x 3's Box of 3's; Alu/White PVC Blister Pack x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-8182 | May 14, 2029 | |
Azi-KidAzithromycin (as dihydrate) | 200 mg/ 5 mL Powder for SuspensionAmber Glass Bottle of 15 mL (net content) with plastic measuring cup x 5 mL (Box of 1's) | Rx | Fredun Pharmaceuticals LimitedIndia | Kaufmann Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-14610-02 | Apr 7, 2027 | |
Aziagio 200Azithromycin (as dihydrate) | 200 mg/ 5mL Oral SuspensionAmber Glass Bottle in 15 mL (net content) Box of 1’s | Rx | Agio Pharmaceuticals Ltd.India | Ambica International Corporation | DRP-5605 | Oct 13, 2029 | |
Azibial-500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletALU/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | Bafna Pharmaceuticals Ltd.India | Medethix, Inc. | DRP-8140 | Mar 21, 2029 | |
AzicareAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's and 30's); Alu/PVC Blister Pack x 3's per Box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Life and Health Source PharmaImporter: Pharmakon Biotec Inc. | DRP-5403-04 | Jul 23, 2029 | |
AzicassAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension32 mL capacity (15 mL net content) amber glass bottle with silver-colored ROPP aluminum cap and 10 mL capacity transparent PP measuring cup (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Cassandras Care Pharmaceutical DistributorImporter: Aglobal Care, Inc. | DRP-13507-03 | Mar 2, 2028 | |
AzicassAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral SuspensionAmber Glass Bottle x 30 mL with 10 mL measuring cup (Box of 1's) | Rx | S Kant Healthcare Ltd.India | Cassandras Care Pharmaceutical DistributorImporter: Medinova Pharmaceutical Inc. | DRP-16281-01 | Jan 27, 2030 | |
AzicassAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3's in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Cassandras Care Pharmaceutical DistributorImporter: Greencore Pharma Inc. | DRP-8640-03 | Mar 2, 2031 | |
AzicenAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu-PVC Blister Pack x 3's (Box of 3s) | Rx | Innova Captab Ltd.India | Airlife International Trading Corporation | DRP-17828 | Mar 17, 2031 | |
AzidenAzithromycin (as dihydrate) | 500 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 1's (Box of 10's) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | Cyden Medicale Trading Inc.Importer: AMB HK Enterprises, Inc. | DRP-12141-01 | Jun 20, 2027 | |
Azifar 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3’s per Box x 10’s (Box of 30’s) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5403-22 | Jul 23, 2029 | |
Azifast-500Azithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/White/Opaque PVC Blister Pack x 3's in monocarton (Box of 30's); Alu/White/Opaque PVC Blister Pack x 3's (Box of 30's); Alu/White/Opaque PVC Blister Pack x 3's (Box of 90's) | Rx | Ipca Laboratories Ltd.India | Blue Global (FZE) | DRP-7472 | Apr 19, 2031 | |
AZIfix 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Medvybe Pharmaceutical TradingImporter: Greencore Pharma, Inc. | DRP-8640-15 | Jan 22, 2030 | |
AZIGRAB 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Grabernoll Pharmaceutical CorporationImporter: Greencore Pharma Inc. | DRP-8640-17 | Jan 22, 2030 | |
Azihold-250Azithromycin (As Dihydrate) | 250 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 6's (Box of 6's) | Rx | Holden Medical Laboratories, Pvt. Ltd.India | Penta Labs Australia (Philippines) | DRP-6362 | Oct 5, 2030 | |
Azihold-500Azithromycin (As Dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 3's (B0x of 3's) | Rx | Holden Medical Laboratories, Pvt., Ltd.India | Penta Labs Australia (Philippines) | DRP-6363 | Oct 5, 2030 | |
AzikAzithromycin (as dihydrate) | 250 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10’s (Box of 50’s) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DRP-10504 | Oct 16, 2036 | |
AzikAzithromycin (as dihydrate) | 500 mg Film-Coated TabletClear PVC/PVDC Alu Blister Pack x 3's (Box of 3's); Clear PVC/PVDC Alu Blister Pack x 10's (Box of 50's) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DRP-10551 | Nov 13, 2031 | |
AzikenAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's and 30's); Alu/PVC Blister Pack x 3's per box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5403-12 | Jul 23, 2029 | |
Azilide DTAzithromycin (as dihydrate) | 100 mg Dispersible TabletAlu/Alu Strip Foil x 5's (Box of 15's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc | DR-XY42600 | Sep 13, 2028 | |
Azilide-250Azithromycin (as dihydrate) | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 6's (Box of 6's); Alu/Alu Blister Pack x 3's (Box of 30's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc | DRP-8772 | Dec 19, 2028 | |
Azilide-500Azithromycin (as dihydrate) | 500 mg Film Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's); Alu/PVC Blister Pack x 3's (Box of 30's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc | DRP-8183 | Dec 19, 2028 | |
Azilife 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Better Option Pharmaceuticals, Inc.Importer: S.M.H.P. Marketing & Consultancy | DR-XY43955 | Dec 10, 2026 | |
AziloAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's and 30's); Alu/PVC Blister Pack x 3's per Box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5403-05 | Jul 23, 2029 | |
AzimacAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension32 mL-capacity Amber glass bottle with aluminum cap x 15 mL-net content (Box of 1's); 60 mL-capacity Amber glass bottle with aluminum cap x 30 mL-net content (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Amediqo Phils., Inc.Importer: Triple Tact Import & Export Corp. | DRP-14138-06 | Jun 30, 2028 | |
AzimacAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Amediqo Phil., Inc.Importer: Greencore Pharma Inc. | DRP-8640-09 | Feb 15, 2031 | |
AzimaxinAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3’s (Box of 3's and 30’s): Alu/PVC Blister Pack x 3’s per box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | NAB Trading Corp.Importer: Pharmakon Biotec Inc. | DRP-5403-21 | Jul 23, 2029 | |
AzimedAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu-Alu Blister Pack x 3's (Box of 9's) | Rx | Ratnamani Healthcare Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-12533 | Aug 30, 2027 | |
Azimex-500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 9's) | Rx | Drug International LimitedBangladesh | JAZMARK PHARMACEUTICAL | DRP-7688 | Nov 19, 2028 | |
AziminAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | Bal Pharma LimitedIndia | Pharmakon Biotec Inc. | DRP-5042 | Jan 7, 2029 | |
AzimitAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's and 30's); Alu/PVC Blister Pack x 3's per box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Quad-Gen PharmaceuticalsImporter: Pharmakon Biotec Inc. | DRP-5403-13 | Jul 23, 2029 | |
Azimoc-500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's); Alu/Clear PVC Blister Pack x 3's in mono carton (Box of 30's) | Rx | Kausikh Therapeutics (P) Ltd.India | Brel Pharmaceutical Inc. | DRP-19134 | Nov 5, 2031 | |
AzimorAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's & 30's); Alu/PVC Blister Pack x 3's per Box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Labmate Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-5403 | Jul 23, 2029 | |
AzipakAzithromycin (as dihydrate) | 200 mg/ 5 mL Powder for SuspensionHDPE White Plastic Bottle with pilfer proof child resistant bottle cap x 15 mL (Box of 1's) | Rx | Opal Laboratories (Pvt.) LimitedPakistan | GEO PAK INTERNATIONAL TRADING CORP.Importer: Accesspoint International Trading Inc. | DRP-5051-02 | Jun 10, 2028 | |
AziprimeAzithromycin (as Dihydrate) | 500 mg TabletAlu/PVC Blister Pack x 3's per box | Rx | Stallion Laboratories Pvt. Ltd.India | Primera Pharma CorporationImporter: Ambica International Corporation | DRP-2985-06 | Jun 16, 2029 | |
AziproAzithromycin (As Dihydrate) | 500mg Film-coated tabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Corona Remedies Private LimitedIndia | Biocare Lifesciences, Inc. | DRP-11061 | Jan 21, 2027 | |
AziqoAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Suspension15 mL HDPE White Colored Plastic Bottle with Pilfer Proof Child Resistant Bottle Cap | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Ellebasy Medicale Group Inc.Importer: Accesspoint International Trading Inc. | DRP-5051-03 | Jun 10, 2028 | |
AziqoAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu / PVC blister pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Ellebasy Medicale Group Inc.Importer: Greencore Pharma Inc. | DRP-8640-12 | Jan 22, 2030 | |
Aziro-500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's and 30's); Alu/PVC Blister Pack x 3's per Box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Meedhaus Pharma, Inc.Importer: Pharmakon Biotec Inc. | DRP-5403-08 | Jul 23, 2029 | |
AzisaphAzithromycin (As Monohydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack Ã- 3's (Box of 3's and 6's) Alu/Alu Blister Pack Ã- 10's (Box of 10's) | Rx | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-6730 | Jul 23, 2031 | |
Azisaph-500Azithromycin (as Dihydrate) | 500 mg Lyophilized Powder for Injection (I.V.)Type I clear glass vial sealed with grey bromobutyl rubber stopper and aluminium cap with plastic flip off seal (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc. | DRP-10637 | Nov 18, 2026 | |
Azisaph-DAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 3's (Box of 3's) | Rx | Sai Parenterals Ltd.India | Nelpa Lifesciences Inc. | DRP-10994 | Jan 23, 2031 | |
AzitanAzithromycin (as Dihydrate) | Lyophilized Powder for Injection | Rx | Gufic Biosciences Ltd. | — | DRP-4217 | Jan 13, 2027 | |
AzitasAzithromycin (as dihydrate) | 200 mg/5 mL Granules for Oral Suspension15 mL Amber PET Bottle with Plastic Measuring Cup (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Orange Biotec Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3248 | Sep 20, 2031 | |
AzitasAzithromycin (as dihydrate) | 500 mg Film -Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | Stallion Laboratories Pvt. Ltd.India | Mirabell Medical Corp.Importer: Orange Biotec Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3456 | Dec 22, 2031 | |
Azitera 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's & 30's); Alu/PVC Blister Pack x 3's per Box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Pill Corp.Importer: Pharmakon Biotec Inc. | DRP-5403-23 | Jul 23, 2029 | |
Azith-ZAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 4's (Box of 4's and 20's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Rhegium Health Trade PharmaImporter: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9320-06 | Sep 11, 2029 | |
AzithcareAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 4's (Box of 4's); Alu/Alu Blister Pack x 3's (Box of 3's) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | Medcare PharmaceuticalsImporter: Sahar International Trading Inc. | DRP-2644-03 | Nov 9, 2029 | |
AzithcorAzithromycin (as dihydrate) | 500 mg Powder for Injection (IV)10 mL USP Type I Glass Vial + 5 mL FFS Sterile Water for Injection (as diluent) in a box | Rx | Gufic Biosciences LimitedIndia | Marcburg Philippines Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4354-03 | Apr 1, 2028 | |
AzithcureAzithromycin | 500 mg TabletAlu / Opaque White PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Jaac Healthline Marketing | DRP-16546-04 | Apr 29, 2030 | |
AzithlevAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension32 mL-capacity Amber glass bottle with aluminum cap x 15 mL-net content ; 60 mL-capacity Amber glass bottle with aluminum cap x 30 mL-net content (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | HLM Pharmaceutical Inc.Importer: Triple Tact Import & Export Corp. | DRP-14138-05 | Jun 30, 2030 | |
AzithlevAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | HLM Pharmaceutical Inc.Importer: Greencore Pharma Inc. | DRP-8640-14 | Jan 22, 2030 | |
AzithlevAzithromycin (as dihydrate) | 500 mg Lyophilized Powder for IV Infusion10 mL USP Type I Clear Mounded Glass Vial in Individual Box of 1's (Box of 10's) | Rx | United Biotech Pvt. Ltd.India | HLM Pharmaceutical, Inc.Importer: Triple Tact Import & Export Corp. | DRP-12746-01 | Oct 5, 2027 | |
AzithraAzithromycin (as dihydrate) | 500mg Film-Coated TabletAlu / PVC Blister Pack x 3’s (Box of 3’s, 15’s, 30’s, 60’s and 90’s) | Rx | Sunrise International Labs LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-15769-01 | Sep 12, 2029 | |
Azithro-NatrapharmAzithromycin (as monohydrate) | 500 mg Film-Coated TabletAlu/White PVC/PVDC Blister Pack x 3's (Box of 3's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Natrapharm, Inc. | DR-XY39058 | Feb 15, 2029 | |
AzithrobbasAzithromycin (as dihydrate) | 500 mg Lyophilized Powder for Injection (IV)Type I Clear Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 1's + 5mL Sterile Water for Injection in Clear Glass Ampoule (Box of 1's and 10's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abba Pharmaceuticals & General Merchandise | DRP-17101 | Sep 29, 2031 | |
AzithrocircAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's per box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | PharmaCircle Enterprise CorporationImporter: Pharmakon Biotec Inc. | DRP-5403-18 | Jul 23, 2029 | |
AzithrodynAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 6’s (Box of 24’s) | Rx | Hizon Laboratories, Inc.Rizal | Nurturemed Pharma, Inc. | DRP-3549-06 | Sep 16, 2036 | |
AzithrogenAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 30's) | Rx | Interphil Laboratories, Inc.Philippines | Nutramedica Inc. | DRP-4391-03 | Apr 29, 2028 | |
AzithrolevAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Umedica Laboratories Pvt. Ltd.India | HLM Pharmaceutical Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-2788-02 | Sep 12, 2031 | |
AzithromAzithromycin | 500 mg Film-Coated TabletAlu/PVC Blister pack x 3's (Box of 3's) | Rx | Anhui Chengshi Pharmaceutical Co., Ltd.China | 2 World Traders Inc.Trader: Ningbo Tisun Medic Biochemic Co., Ltd. | DR-XY45478 | Jun 30, 2031 | |
AzithroMaxAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | Stallion Laboratories Pvt. Ltd.India | Dreamax IncorporatedImporter: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3456-02 | Dec 22, 2026 | |
AzithronovaAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 1's) | Rx | Zim Laboratories LimitedIndia | Medinova Pharmaceutical Inc. | DRP-10620 | Dec 9, 2026 | |
AzithrosaveAzithromycin (as dihydrate) | 200 mg / 5 mL Powder for Suspension15 mL HDPE White Colored Plastic Bottle with Pilfer Proof Child Resistant Bottle Cap | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Savelink Pharma and Trading Co.Importer: Accesspoint International Trading Inc. | DRP-5051-04 | Jun 10, 2028 | |
AzithrosaveAzithromycin (as dihydrate) | 200 mg/ 5 mL Powder for Oral Suspension32 mL capacity (15 mL net content) amber glass bottle with silver-colored ROPP aluminum cap and 10 mL capacity transparent PP measuring cup (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Savelink Pharma And Trading Co.Importer: Aglobal Care, Inc. | DRP-13507-07 | Mar 2, 2028 | |
AzithrospeedAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 30's) | Rx | Interphil Laboratories, Inc.Philippines | Speed Med Pharmaceuticals | DRP-4391-08 | Apr 29, 2028 | |
AzithrovinAzithromycin (as Monohydrate) | 500 mg Film-Coated TabletAlu/White PVC Blister Pack x 3's (Box of 3's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vamsler Phils. Incorporated | DRP-7476 | Jan 4, 2027 | |
AzithrxAzithromycin (as dihydrate) | 500 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Fip-Off Seal Cap + Type I Clear Colorless Glass Ampoule x 10 ml (net content) as diluent (Sterile Water for Injection) (Box of 10's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-12141 | Jun 20, 2032 | |
AzithsaveAzithromycin (as dihydrate) | 200 mg/ 5 mL Powder for Oral Suspension32 mL capacity (15 mL content) amber glass bottle with silver-colored ROPP aluminum cap and 10 mL capacity transparent PP measuring cup (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Curasave PharmaImporter: Aglobal Care, Inc. | DRP-13507-08 | Mar 2, 2028 | |
AzithvaAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 30's); Alu/PVC Blister Pack x 3's per Box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5403-09 | Jul 23, 2029 | |
AzithwellAzithromycin (as Dihydrate) | 200 mg/5 mL Powder for SuspensionPET Amber Bottle x 15 mL (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | TGIF Pharmaceutical Trading Inc.Importer: Ambica International Corporation | DRP-3322-03 | Jul 8, 2029 | |
Azitobact 500Azithromycin (as Dihydrate) | 500mg Film-Coated TabletAlu-PVC/PVdC blister pack x 3 tablets (Box of 3 tablets) | Rx | Zim Laboratories LimitedIndia | Medinova Pharmaceutical Inc. | DRP-8289 | Aug 5, 2027 | |
AzitritecAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's and 30's) | Rx | Sunrise International Labs LimitedIndia | Despina Pharma Inc. | DRP-15769 | Sep 12, 2029 | |
Aziv 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's and 30's); Alu/PVC Blister Pack x 3's per box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5403-07 | Jul 23, 2029 | |
Azivid-500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's and 30's); Alu/PVC Blister Pack x 3's per box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | All Bio Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-5403-16 | Jul 23, 2029 | |
AzivolAzithromycin Dihydrate | 500 mg Lyophilized Powder for IV SolutionType I glass vial x 10 mL-capacity with grey bromobutyl rubber stopper, aluminum seal, and orange flip-off cap (Box of 1's) | Rx | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY49755 | Jun 18, 2031 | |
AzmicinAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 30's); Alu/PVC Blister Pack x 3's per Box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | NJT EnterprisesImporter: Pharmakon Biotec Inc. | DRP-5403-10 | Jul 23, 2029 | |
Azmyn IVAzithromycin (as dihydrate) | 500 mg Powder for Solution for I. V. Infusion10 mL capacity USP Type III clear and colorless glass vial with bromobutyl rubber stopper and aluminum seal with plastic flip-off cap (box of 1's) | Rx | Alwin DMD PharmaceuticalsIndia | Bliss Pharma Distribution and Consultancy Corp. | DRP-15254 | May 31, 2029 | |
Azo 500Azithromycin (As Dihydrate) | 500 mg Film-Coated TabletAlu-Alu blister pack x 3's (Box of 6's) | Rx | Delta Pharma LimitedBangladesh | Biomed Pharma Inc. | DR-XY38264 | Jul 19, 2031 | |
AzolvAzithromycin (as monohydrate) | 200 mg/5 mL Powder for SuspensionHDPE White Opaque Plastic Bottle x 22.5 mL with measuring cup (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Dr. Zen’s Research, Inc.Trader: Solvang Pharmaceuticals, Inc. | DRP-15628-01 | Mar 13, 2030 | |
AzomacAzithromycin (as Dihydrate) | 200mg/5mL Powder for SuspensionUSP Type III Amber Glass Bottle x 15 mL and 30 mL (Box of 1's) | Rx | General Pharmaceuticals Ltd.Bangladesh | Healol Pharma Corporation | DR-XY38805 | Dec 3, 2027 | |
AzomacAzithromycin (as Dihydrate) | 500mg Film-Coated TabletAlu/Alu Blister Pack x 3's (Box of 3's and 6's) | Rx | — | Healol Pharma Corporation | DR-XY38806 | Dec 3, 2027 | |
Azor-500Azithromycin (as dihydrate) | 500 mg Film Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | East African (India) OverseasIndia | Airlife International Trading Corporation | DRP-14722 | Dec 13, 2028 | |
AzralidAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Labmate Pharma Inc.Importer: Greencore Pharma Inc. | DRP-8640-02 | Feb 9, 2031 | |
AzroAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension15 mL (net content) in 30 mL capacity amber glass bottle with silver colored pilfer-proof aluminum screw cap and 10 mL capacity PP measuring cup (Box of 1's) | Rx | S Kant Helathcare LimitedIndia | Ellebasy Medicale Group Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15520-01 | Jul 31, 2029 | |
AzroAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3's packed in monocarton (Box of 10's) | Rx | Theon Pharmaceuticals LimitedIndia | Ellebasy Medicale Group Inc.Importer: Greencore Pharma Inc. | DRP-8640-10 | Feb 20, 2031 | |
AzrockAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Umedica Laboratories Pvt. Ltd.India | Redrocks Pharma and Medical Supplies DistributionImporter: Suhitas Pharmaceuticals Inc. | DRP-2788-03 | Sep 12, 2031 | |
AzthrocureAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 3's (Box of 3's) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-4885 | Nov 4, 2028 | |
AztocinAzithromycin (as dihydrate) | 200 mg / 5 mL Powder for Suspension15 mL HDPE white colored plastic bottle with pilfer proof child resistant bottle cap | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc. | DRP-5051-01 | Jun 10, 2028 | |
AztrocinAzithromycin (as dihydrate) | 250 mg CapsuleRed PVC Blister Pack x 10's in a box | Rx | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DR-XY35341 | Jan 29, 2031 | |
AztrocinAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Terramedic, Inc. | DRP-8407-01 | Feb 10, 2032 | |
AztrozinAzithromycin (as dihydrate) | 500 mg Powder for IV InfusionType I Clear Glass Vial with Blue Flip-Off Seal (Box of 10’s) | Rx | Jiangsu Kingsley Pharmaceutical Co., Ltd.China | Global PharmatradeTrader: Mecechem (Wuxi) Co., Ltd. | DR-XY43776 | Oct 2, 2029 | |
AzurillAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension30 mL-capacity amber glass bottle with aluminum cap (Box of 1's) | Rx | S Kant Healthcare Ltd.India | Biocare Lifesciences, Inc. | DRP-17307 | Nov 14, 2030 | |
AzurinAzithromycin | 500 mg Film-coated TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-16984 | Sep 3, 2030 | |
Azyth DAzithromycin (as dihydrate) | 200 mg per 5 mL Powder for Oral SuspensionHDPE Bottle x 15 mL in 30 mL, 22.5 mL in 30 mL, 30 mL in 60 mL and 37.5 mL in 60 mL with 10 mL plastic oral syringe (Box of 1's) | Rx | Sandoz S.R.L.Romania | Sandoz Philippines Corporation | DRP-17252 | Oct 24, 2030 | |
Azyth DAzithromycin (as dihydrate) | 500 mg Film Coated TabletAlu/PVC/PVDC Blister Pack x 3's (Box of 3's) | Rx | Sandoz S.R.L.Romania | Sandoz Philippines Corporation | DRP-17067 | Sep 23, 2030 | |
AzythanAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu / Clear PVC Blister Packs x 3's (Box of 3's) | Rx | Bafna Pharmaceuticals Ltd.India | Vitalife Pharma & Medical Supply Inc.Importer: Medethix, Inc. | DRP-8140-04 | Mar 21, 2029 | |
AzythrexAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension32 mL capacity (15 mL net content) amber glass bottle with silver-colored ROPP aluminum cap and 10 mL capacity transparent PP measuring cap (Box of 1’s) | Rx | S Kant Healthcare LimitedIndia | Euroasia Pharmaceuticals, IncImporter: Aglobal Care, Inc. | DRP-13507-06 | Mar 2, 2028 | |
AzythrexAzithromycin (as dihydrate) | 500 mg Film Coated TabletAlu/Alu Blister Pack x 3's (Box of 3's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Euroasia Pharmaceuticals, Inc. | DRP-13232 | Jan 5, 2028 | |
AzythrexAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | Bal Pharma LimitedIndia | Euroasia Pharmaceuticals, Inc.Importer: Pharmakon Biotec Inc. | DRP-5042-01 | Jan 7, 2029 | |
BerzimaxAzithromycin | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3’s (Box of 3’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Neo-Care PhilippinesImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3204-04 | Sep 1, 2029 | |
Berzimax-500Azithromycin (as dihydrate) | 500 mg Powder for Injection (IV)10 mL USP Type I Glass Vial + 5 mL FFS Sterile Water for Injection as Diluent (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | Neo-Care PhilippinesImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4354-05 | Apr 1, 2028 | |
BiomacAzithromycin (as dihydrate) | 200 mg/5 mL Powder for SuspensionAmber Bottle x 15 mL w/ 1.2 mL Dropper & 35 mL w/ 5 mL Plastic Measuring Spoon (Box of 1's); | Rx | Biopharma Laboratories LimitedBangladesh | All-Bio Pharma, Inc.Importer: JF Draft Pharmaceuticals Corporation | DRP-5134-01 | Feb 13, 2029 | |
Blizeth 500 TAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack of 3's (Box of 3's) | Rx | Next Wave (India)India | Bliss Pharma Distribution and Consultancy Corp. | DRP-15521 | Jul 31, 2029 | |
CenzitAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3’s (Box of 3's and 30's) | Rx | Sunrise International Labs LimitedIndia | Central West Medicale Inc.Importer: Despina Pharma Inc. | DRP-15769-03 | Sep 12, 2029 | |
CinazithAzithromycin (as Dihydrate) | 500 mg TabletAlu/PVC Blister Pack x 3's per box | Rx | Stallion Laboratories Pvt. Ltd.India | D & G PharmaImporter: Ambica International Corporation | DRP-2985-05 | Jun 16, 2029 | |
Cinazith-DSAzithromycin (as dihydrate) | 200 mg/ 5 mL Oral SuspensionAmber Glass Bottle in 15 mL (net content) (Box of 1’s) | Rx | Agio Pharmaceuticals Ltd.India | D&G PharmaImporter: Ambica International Corporation | DRP-5605-01 | Oct 13, 2029 | |
Cinazith-DSAzithromycin (as Monohydrate) | 200 mg/5 mL SuspensionAmber Glass Bottle x 15 mL and 30 mL with 5 mL and 10 mL Transparent LDPE Measuring Cup (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | D&G PharmaImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3431-09 | Dec 7, 2029 | |
Cinazith-DSAzithromycin (as dihydrate) | 200 mg/5mL Powder for SuspensionPET Amber Bottle x 15 mL (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | D & G PharmaImporter: Ambica International Corporation | DRP-3322-02 | Jul 8, 2029 | |
Cozith-SAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3‘s (Box of 3’s) | Rx | Zim Laboratories Ltd.India | Pharmasilv TradingImporter: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.) | DRP-2170-02 | Mar 21, 2031 | |
CozithroAzithromycin (as dihydrate) | 500mg Film-Coated TabletAlu/Alu Blister Pack x 3's (Box of 3's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Pharmacom DistributionImporter: AGlobal Care, Inc. | DRP-13692-01 | Apr 13, 2028 | |
CupidAzithromycin | 500 mg Film-Coated TabletPVC/Alu Blister Pack x 3’s (Box of 3’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Virrod Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3204-10 | Sep 1, 2029 | |
DafzithAzithromycin | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3’s (Box of 3’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | JVZEA Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3204-06 | Sep 1, 2029 | |
EaonmaxAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVDC Blister Pack x 3's (Box of 3's) | Rx | The ACME Laboratories LimitedBangladesh | Eaon EnterpriseImporter: Euro Generics International Phils., Inc. | DRP-3637-03 | Sep 19, 2031 | |
EdutrozinAzithromycin (as dihydrate) | 500 mg Powder for Injection (IV)10 mL USP Type I Glass Vial + 5 mL FFS Sterile Water for Injection (as Diluent) in a box | Rx | Gufic Biosciences LimitedIndia | Edu Pharma EnterpriseImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4354-06 | Apr 1, 2028 | |
EnazAzithromycin (as dihydrate) | 500 mg Powder for Injection (IV)10 mL USP Type I Glass Vial + 5 mL FFS Sterile Water for Injection in a box | Rx | Gufic Biosciences LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4354-01 | Apr 1, 2028 | |
Enaz DSAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension15 mL White coloured HDPE Plastic Bottle with measuring cup in a box Not Applicable | Rx | Stallion Laboratories Pvt. Ltd.India | Central West Medicale Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Endurance Healthcare Pvt. Ltd. | DRP-6333 | Feb 7, 2037 | |
Enaz-250Azithromycin (as dihydrate) | 250 mg Film-Coated TabletAlu/PVC Blister Pack x 6's (Box of 60's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-4736 | Sep 26, 2028 | |
Enaz-500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-4733 | Sep 26, 2028 | |
EzythromaxAzithromycin (as monohydrate) | 200 mg/5 mL SuspensionAmber Glass Bottle x 15 mL with 5 mL Transparent LDPE Measuring Cup (Box of 1’s); Amber Glass Bottle x 30 mL with 10 mL Transparent LDPE Measuring Cup (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Guimhealth Pharmaceutical Distributor and DrugstoreImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3431-05 | Dec 7, 2029 | |
EzythromaxAzithromycin | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3’s Box of 3’s | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Guimhealth Pharmaceutical Distributor & DrugstoreImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3204-03 | Sep 1, 2029 | |
GeozitAzithromycin (as dihydrate) | 250 mg CapsuleAlu/Alu Blister Pack x 5's (Box of 10's) | Rx | Geofman PharmaceuticalsPakistan | Sahar International Trading Inc. | DRP-2646 | Mar 10, 2029 | |
GizithAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Gijun Trading Inc.Importer: Greencore Pharma Inc. | DRP-8640-05 | Feb 9, 2031 | |
GmycinAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 4's (Box of 4's); Alu/Alu Blister Pack x 3's (Box of 3's) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | Ferma Drug EnterprisesImporter: Sahar International Trading Inc. | DRP-2644-02 | Nov 9, 2029 | |
GozibactAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu-Alu Blister packs x 3's (Box of 3's and Box of 30's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc. | DRP-12533-01 | Aug 30, 2027 | |
GozimaxAzithromycin | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3’s (Box of 3’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Applied Pharmaceutical Distribution Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3204-01 | Sep 1, 2029 | |
GozimaxAzithromycin (as dihydrate) | 500 mg Powder for Injection (IV)10 mL USP Type I Glass Vial + 5 mL FFS Sterile Water for Injection (as diluent) in a box | Rx | Gufic Biosciences LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4354-02 | Apr 1, 2028 | |
GozinatAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension32 mL-capacity Amber glass bottle with aluminum cap x 15 mL-net content (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Applied Pharmaceutical Distribution IncImporter: Triple Tact Import & Export Corp. | DRP-14138-01 | Jun 30, 2028 | |
GozinatAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3 's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Applied Pharmaceutical Distribution IncImporter: Greencore Pharma Inc. | DRP-8640-06 | Feb 9, 2031 | |
Gozinat IVAzithromycin (as dihydrate) | 500 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap + Type I Clear Colorless Glass Ampoule x 10 mL as diluent (Sterile Water for Injection) (Box of 10’s) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution IncImporter: AMB HK Enterprises Inc. | DRP-12141-02 | Jun 20, 2027 | |
GoziroxAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu-PVC Blister Pack x 3's (Box of 3's) | Rx | AMN Life Pvt. Ltd.India | Go Healthcare Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc. | DRP-12544-01 | Aug 31, 2027 | |
Gozith IVAzithromycin (as dihydrate) | 500 mg Powder for Injection (IM/IV)10 mL USP Type I Glass Vial + 5 mL FFS Sterile Water for Injection (as diluent) in a box | Rx | Gufic Biosciences LimitedIndia | Diafarm Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4354-07 | Apr 1, 2028 | |
GozithranAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu-PVC/PVdC blister pack x3 tablets (Box of 3 tablets) | Rx | Zim Laboratories LimitedIndia | Go Healthcare Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc. | DRP-8289-02 | Aug 5, 2027 | |
GozithroAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension32 mL Capacity (15 mL net content) amber glass bottle with sliver-colored ROPP aluminum cap and 10 mL with silver-colored ROPP aluminum cap and 10 mL capacity transparent PP measuring cup (Box of 1's) | Rx | S KANT HEALTHCARE LIMITEDIndia | GO HEALTHCARE PHARMACEUTICAL DISTRIBUTIONImporter: AGLOBAL CARE, INC. | DRP-13507-04 | Mar 2, 2028 | |
HepsesAzithromycin | 500 mg Film-Coated TabletPVC/Alu Blister Pack x 3’s (Box of 3’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Diafarm Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3204-08 | Sep 1, 2029 | |
HithroAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | HLM Pharmaceutical Inc.Importer: Greencore Pharma Inc. | DRP-8640-04 | Feb 9, 2031 | |
HithroAzithromycin (as Dihydrate) | 500 mg Lyophilized Powder For Injection ( I.V. Infusion)10 mL USP Type I Clear Mounded Glass Vial in individual box of 1's (Box of 10's) | Rx | United Biotech Pvt. Ltd.India | Triple Tact Import & Export Corp. | DRP-12746 | Oct 5, 2027 | |
ImazAzithromycin (as dihydrate) | 500 mg Lyophilized Powder for IV InfusionUSP Type I Glass Vial x 10 mL + Clear Ampoule x 5 mL Diluent (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | SRS Life Sciences Inc. | DRP-4213 | Dec 6, 2032 | |
JanzithAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | Bal Pharma LimitedIndia | Jjysrinn Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5042-03 | Jan 7, 2029 | |
Jazit 500Azithromycin (as dihydrate) | 500 mg TabletAlu/Alu blister pack of 3's (Box of 6's) | Rx | Somatec Pharmaceuticals Ltd.Bangladesh | Medicamenta Inc.Importer: Bridgemark Marketing | DRP-3586-01 | Apr 28, 2027 | |
JiaamycinAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3’s (Box of 3’s) | Rx | Umedica Laboratories Pvt. Ltd.India | Jiaa PharmaImporter: Suhitas Pharmaceuticals Inc. | DRP-2788-04 | Nov 12, 2030 | |
JiaamycinAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 3's (Box of 3's) | Rx | Stallion Laboratories Pvt. Ltd.India | Jiaa PharmaImporter: Orange Biotec Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3456-01 | Dec 22, 2031 | |
KotrazithAzithromycin (as dihydrate) | 500 mg Lyophilized Powder for Injection for I.V. InfusionType 1 clear glass vial with grey bromobutyl rubber, aluminum cap seal and blue plastic flip-off (Box of 10's) | Rx | Kotra Pharma (M) SDN. BHDMalaysia | Bliss Pharma Distribution and Consultancy Corp. | DRP-15868 | Sep 25, 2029 | |
M-zith IVAzithromycin (as monohydrate) | 500 mg Lyophilized Powder for Solution for IV Infusion10 mL capacity USP Type I Clear Glass Vial Stoppered with Bromobutyl Rubber Stopper and Sealed with Aluminum Blue Flip-Off Seal Box of 1's | Rx | Gland Pharma LimitedIndia | Biocare Lifesciences, Inc. | DRP-9119 | Oct 20, 2030 | |
Maczithro-DSAzithromycin (as dihydrate) | 100 mg/5 mL SuspensionAmber Glass Bottle x 15 mL (Box of 1's) | Rx | Agio Pharmaceuticals Ltd.India | Prodrom Nutritionals, IncorporatedImporter: Ambica International Corporation | DRP-4705 | Sep 11, 2028 | |
MaxithroAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu-PVC Blister Pack x 3's (Box of 3's) | Rx | AMN Life Pvt. Ltd.India | Beracah Pharma Phils., Inc.Importer: Medinova Pharmaceutical Inc. | DRP-12544-05 | Aug 31, 2027 | |
MedibioticAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu-PVC Blister Pack x 3's (Box of 3's) | Rx | AMN Life Pvt. Ltd.India | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-12544-02 | Aug 31, 2027 | |
MyaziAzithromycin (as monohydrate) | 200 mg/5 mL SuspensionAmber Glass Bottle x 15 mL with 5 mL Transparent LDPE Measuring Cup (Box of 1’s); Amber Glass Bottle x 30 mL with 10 mL Transparent LDPE Measuring Cup (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Preventia Healthcare Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3431-07 | Dec 7, 2029 | |
MYAZI 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Preventia Healthcare Inc.Importer: Greencore Pharma Inc. | DRP-8640-16 | Jan 22, 2030 | |
MycigenAzithromycin | 500 mg TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-16546-02 | Apr 29, 2030 | |
MykmaxinAzithromycin | 500 mg Film-Coated TabletPVC/Alu Blister Pack x 3’s Box of 3’s | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | West Wing Pharma Sales Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3204-07 | Sep 1, 2029 | |
NoneAzithromycin | 200 mg / 5 mL SuspensionAmber Glass Bottle x 15 mL with 5 mL Transparent LDPE Measuring Cup (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant II)India | PharmaVital Corp.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3431-11 | Dec 7, 2029 | |
NoneAzithromycin (as dihydrate) | 200 mg/ 5 mL Powder for SuspensionAmber Glass Bottle of 15 mL (net content) with plastic measuring cup x 5 mL (Box of 1's) | Rx | Fredun Pharmaceuticals LimitedIndia | Kaufmann Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-14610-01 | Apr 7, 2027 | |
NoneAzithromycin (as dihydrate) | 200 mg/ 5 mL Powder for Suspension30 mL HDPE White Colored Plastic Bottle with Pilfer Proof Child Resistant Bottle Cap | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Bio Erixx Pharma DistributionImporter: Accesspoint International Trading Inc. | DRP-5051-07 | Jun 10, 2028 | |
NoneAzithromycin (as dihydrate) | 200 mg/5 mL Powder for SuspensionPET Amber Bottle x 15 mL (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3322-01 | Jul 8, 2029 | |
NoneAzithromycin (as dihydrate) | 250 mg Film-Coated TabletAluminum foil strip x 4's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | Neodrug, Inc. | DRP-4388-01 | Apr 29, 2028 | |
NoneAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 3's (Box of 3's) | Rx | Sapphire Lifesciences Pvt. Ltd.India | TGP Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-10994-02 | Dec 31, 2026 | |
NoneAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Zim Laboratories LimitedIndia | MedEthix, Inc.Importer: I.E. Medica, Inc. | DRP-17501 | Jun 8, 2031 | |
NoneAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 3's, 28's and 100's) | Rx | Interphil Laboratories, Inc.Philippines | Neodrug, Inc. | DRP-4391-01 | Apr 29, 2028 | |
NoneAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | Rose Pharmacy Incorporated | DRP-4391-05 | Apr 29, 2028 | |
NoneAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 3's (Box of 3's) | Rx | Interphil Laboratories, Inc.Philippines | Natrapharm Inc. | DRP-4391-06 | Apr 29, 2028 | |
NoneAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 2's, 12's, 28's, 30's and 100's) | Rx | Interphil Laboratories, Inc.Philippines | South Star Drug | DRP-4391-09 | Apr 29, 2028 | |
NoneAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 9's) | Rx | Drug International LimitedBangladesh | Bridgemark MarketingImporter: Jazmark Pharmaceutical | DRP-7688-02 | Nov 19, 2028 | |
NoneAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/ Clear PVC Blister Pack x 3's (Box of 3's) | Rx | Bafna Pharmaceuticals Ltd.India | Patriot Pharmaceuticals CorporationImporter: Medethix, Inc. | DRP-8140-03 | Mar 21, 2029 | |
NoneAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu-PVC/PVdC Blister Pack x 3 tablets (Box of 3 tablets) | Rx | Zim Laboratories LimitedIndia | Qualifirst Health Inc.Importer: Medinova Pharmaceutical Inc. | DRP-8289-03 | Aug 5, 2027 | |
NoneAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-8407 | Feb 10, 2027 | |
NoneAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC PVDC Blister Pack x 3's (Box of 3's) | Rx | Ind-Swift LimitedIndia | Ritemed Phils., Inc. | DRP-8453 | Dec 19, 2029 | |
NoneAzithromycin (as dihydrate) | 500 mg Film-Coated TabletWhite opaque PVC/Alu Blister Pack x 3's (Box of 3's) | Rx | Viatris Pharmaceuticals LLCUSA | Philusa CorporationImporter: Pfizer, Inc. | DRP-8702-01 | Feb 7, 2030 | |
NoneAzithromycin (as dihydrate) | 500 mg Powder for Injection (IV)USP Type I Glass Vial + 5 mL FFS Sterile Water for Injection (as diluent) in a Box | Rx | Gufic Biosciences LimitedIndia | Lifegen Distribution Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4354-04 | Apr 1, 2028 | |
NoneAzithromycin (as dihydrate) | 500 mg Powder for Solution for I.V. Infusion10 mL capacity USP Type III clear and colorless glass vial with bromobutyl rubber stopper and aluminum seal with plastic flip-off cap (Box of 1's) | Rx | Alwin DMD PharmaceuticalsIndia | Amediqo Phils., Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15254-01 | May 31, 2029 | |
NoneAzithromycin (as Dihydrate) | 500 mg TabletAlu/PVC Blister Pack x 3's per box | Rx | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International Corporation | DRP-2985-11 | Jun 16, 2029 | |
NoneAzithromycin (as dihydrate) | 500 mg TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Mediwin PharmaceuticalsIndia | Actimed, Inc.Importer: Ambica International Corporation | DRP-5838-02 | Nov 20, 2029 | |
NovazithAzithromycin(As Dihydrate) | 500 mg Film Coated TabletAlu-PVC Blister Pack x 3's (Box of 3's) | Rx | AMN Life Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-12544 | Aug 31, 2027 | |
NovazithroAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral SuspensionAmber Glass Bottle x 30 mL with 10 mL measuring cup (Box of 1's) | Rx | S Kant Healthcare Ltd.India | Medinova Pharmaceutical Inc. | DRP-16281 | Jan 27, 2030 | |
OD MacAzithromycin (as dihydrate) | 500 mg TabletBlister Pack x 3's (Box of 30's) | Rx | Medibios Laboratories Pvt. LtdIndia | IBERICA VERHEILEN PHARMACEUTICALS GROUP CORP.Importer: VERHEILEN IBERICA HEALTH CARE COMPANY INC.Trader: Farma Iberica SL | DRP-4288 | Oct 12, 2029 | |
OrabacAzithromycin (as dihydrate) | 200 mg/5 mL Granules for Oral Suspension15 mL Amber PET Bottle with Plastic Measuring Cup (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Importer: Orange Biotec Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3248-02 | Sep 20, 2036 | |
PediazithAzithromycin (as Dihydrate) | 200 mg/5 mL Powder for SuspensionPET Amber Bottle x 15 mL (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Medlink Pharma Phils., Inc.Importer: Ambica International Corporation | DRP-3322-04 | Jul 8, 2029 | |
PhartobacAzithromycin (as Dihydrate) | 200 mg/5 mL Powder for SuspensionPET Amber Bottle x 15 mL (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Pharmworld IncorporatedImporter: Ambica International Corporation | DRP-3322-07 | Jul 8, 2029 | |
ProzitroAzithromycin (as Dihydrate) | 500 mg TabletAlu/PVC Blister Pack x 3's per box | Rx | Stallion Laboratories Pvt. Ltd.India | Central West Medicale Inc.Importer: Ambica International Corporation | DRP-2985-10 | Jun 16, 2029 | |
Prozitro-DSAzithromycin (as monohydrate) | 200 mg/5 mL SuspensionAmber Glass Bottle x 15 mL with 5 mL Transparent LDPE Measuring Cup Box of 1’s; Amber Glass Bottle x 30 mL with 10 mL Transparent LDPE Measuring Cup Box of 1’s | Rx | Akums Drugs & Pharmaceuticals Ltd.India | PFC Drug Distributors Company Ltd.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3431-03 | Dec 7, 2029 | |
RespazitAzithromycin (as dihydrate) | 500 mg TabletAlu/Alu blister pack of 3's (Box of 6's) | Rx | Somatec Pharmaceuticals Ltd.Bangladesh | Medirich Pharma Distribution Corp.Importer: Bridgemark Marketing | DRP-3586 | Apr 28, 2027 | |
RetamaxzAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension15 mL (net content) in 30 mL capacity amber glass bottle with silver colored pilfer-proof aluminum screw cap and 10 mL capacity PP measuring cup (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Reta DrugImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-15520-02 | Jul 31, 2029 | |
RetamaxzAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x3’s (Box of 3’s) | Rx | Umedica Laboratories Pvt. Ltd.India | Reta DrugImporter: Suhitas Pharmaceuticals Inc. | DRP-2788-05 | Nov 12, 2030 | |
RetamaxzAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/ PVC blister pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Reta DrugImporter: Greencore Pharma Inc. | DRP-8640-07 | Feb 9, 2031 | |
RetamxcinAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension32 mL capacity (15 mL net content) amber glass bottle with silver - colored ROPP aluminum cap and 10 mL capacity transparent PP measuring cup (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Reta DrugImporter: Aglobal Care, Inc. | DRP-13507-02 | Mar 2, 2028 | |
RetamycinAzithromycin (as dihydrate) | 200 mg/5 mL Granules for Oral Suspension15 mL Amber PET Bottle with Plastic Measuring Cup (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Reta DrugImporter: Orange Biotec Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3248-08 | Sep 20, 2031 | |
RetazithAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | AMN Life Pvt. Ltd.India | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-12544-04 | Aug 31, 2027 | |
RexithroAzithromycin (as Dihydrate) | 200 mg/5 mL Powder for SuspensionPET Amber Bottle x 15 mL (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Rexmed Pharmaceutical SalesImporter: Ambica International Corporation | DRP-3322-05 | Jul 8, 2029 | |
RexithroAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's per Box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Rexmed Pharmaceutical SalesImporter: Pharmakon Biotec Inc. | DRP-5403-11 | Jul 23, 2029 | |
Rexithro LQAzithromycin (as monohydrate) | 200 mg/5 mL SuspensionAmber Glass Bottle x 15 mL with 5 mL Transparent LDPE Measuring Cup Box of 1’s; Amber Glass Bottle x 30 mL with 10 mL Transparent LDPE Measuring Cup Box of 1’s | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Rexmed Pharmaceutical SalesImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3431-08 | Dec 7, 2029 | |
RifethromycinAzithromycin (as dihydrate) | 500 mg Powder for Injection (IV)10 mL USP Type I Glass Vial + 5 mL FFS Sterile Water for Injection (as diluent) in a box | Rx | Gufic Biosciences LimitedIndia | Rifemedica CorporationImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4354-08 | Apr 1, 2028 | |
RomycinAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension35 mL-capacity USP Type III Amber glass bottle with aluminum cap x * 15 mL-net content with plastic measuring cup and dropper in a box | Rx | The IBN SINA Pharmaceutical Industry Ltd.Bangladesh | Eaon EnterpriseImporter: Euro Generics International Phils., Inc. | DR-XY48967 | Dec 28, 2028 | |
RozentaAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension32 mL-capacity Amber glass bottle with aluminum cap x 15 mL-net content (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Trumed PharmaceuticalsImporter: Triple Tact Import & Export Corp. | DRP-14138-02 | Jun 30, 2028 | |
RozentaAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Trumed PharmaceuticalsImporter: Greencore Pharma Inc. | DRP-8640-08 | Feb 15, 2031 | |
RozitanAzithromycin (as dihydrate) | 200 mg/ 5 mL Powder for SuspensionAmber Glass Bottle of 15 mL (net content) with plastic measuring cup x 5 mL (Box of 1's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DR-XY44401 | Apr 7, 2027 | |
RozitanAzithromycin (as dihydrate) | 200 mg/ 5 mL Powder for SuspensionAmber Glass Bottle of 15 mL (net content) with plastic measuring cup x 5 mL (Box of 1's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-14610 | Apr 7, 2027 | |
S-TrozAzithromycin (as dihydrate) | 500 mg TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Mediwin PharmaceuticalsIndia | Starpharm, Inc.Importer: Ambica International Corporation | DRP-5838-01 | Nov 20, 2029 | |
SITIMAXAZITHROMYCIN (AS DIHYDRATE) | 500 MG FILM-COATED TABLETALU/ALU BLISTER PACK X 4'S AND ALU/ALU BLISTER PACK X 3'S (BOX OF 4'S AND BOX OF 3'S) | Rx | CSPC OUYI PHARMACEUTICAL CO. LTD.China | SAHAR INTERNATIONAL TRADING INC | DRP-2644 | Nov 9, 2029 | |
SITIMAXAzithromycin (as dihydrate) | 500 mg Lyophilized Powder for Injection (IV)Clear USP Type I glass vial | Rx | CSPC OUYI PHARMACEUTICAL CO., LTDChina | Importer: SAHAR INTERNATIONAL TRADING INC. | DRP-7050 | Aug 3, 2027 | |
Sitimax-200Azithromycin (as dehydrate) | 200 mg/5 mL Powder for Oral SuspensionUSP Type III Amber Glass Bottle x 15 mL (Box of 1's) | Rx | Geofman PharmaceuticalsPakistan | Sahar International Trading Inc. | DR-XY42983 | Nov 19, 2028 | |
Sitimax-500Azithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister x 5's (Box of 5's) | Rx | Geofman PharmaceuticalsPakistan | Sahar International Trading Inc | DR-XY39908 | Aug 11, 2031 | |
Skythro-500Azithromycin (as dihydrate) | 500 mg TabletAlu/PVC Blister Pack x 3's Box of 3's | Rx | Mediwin PharmaceuticalsIndia | Ambica International Corporation | DRP-5838 | Nov 20, 2029 | |
StrozinAzithromycin (as dihydrate) | 200 mg/5mL Powder for SuspensionPET Amber Bottle x 15mL Box of 1's | Rx | Stallion Laboratories Pvt. Ltd.India | Starpharm, Inc.Importer: Ambica International Corporation | DRP-3322-08 | Jul 8, 2029 | |
StrozinAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3‘s (Box of 3’s) | Rx | Zim Laboratories Ltd.India | Starpharm, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.) | DRP-2170-01 | Apr 1, 2031 | |
SupmacAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3’s (Box of 3’s) | Rx | Umedica Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-2788 | Nov 12, 2030 | |
Throinfec DSAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension15 mL (net content) in 30 mL capacity amber glass bottle with silver colored pilfer-proof aluminum screw cap and 10 mL capacity PP measuring cup (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Bliss Pharma Distribution and Consultancy Corp. | DRP-15520 | Jul 31, 2029 | |
ThromaxinAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVDC Blister Pack x 3's (Box of 3's) | Rx | The ACME Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DRP-3637 | Dec 7, 2030 | |
Thromic-500Azithromycin (as dihydrate) | 500 mg CapsuleAlu/Clear PVC Blister Pack x 3's (Box of 1's); Alu/Clear PVC Blister Pack x 4's (Box of 1's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Dynasty PharmaceuticalsImporter: AMB HK Enterprises Inc. | DRP-7914-02 | Feb 15, 2032 | |
Throx500Azithromycin (as dihydrate) | 500 mg Film-coated TabletAlu/PVC Blister Pack x 3's (Box of 1's) | Rx | Zim Laboratories LimitedIndia | MedEthix, Inc.Importer: I.E. Medica, Inc. | DRP-9487 | Aug 16, 2031 | |
ThroxoconAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVDC Blister Pack x 3's (Box of 3's) | Rx | The ACME Laboratories LimitedBangladesh | D'Conner PharmaImporter: Euro Generics International Phils., Inc. | DRP-3637-04 | Dec 7, 2030 | |
ThrozitechAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 3's (Box of 3's) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-10994-03 | Dec 31, 2026 | |
TrishulAzithromycin (as monohydrate) | 200 mg/5 mL SuspensionAmber Glass Bottle x 15 mL and 30 mL with 5 mL and 10 mL Transparent LDPE Measuring Cup (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Diafarm, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3431-06 | Dec 7, 2029 | |
TromyznAzithromycin (as dihydrate) | 500 mg TabletAlu / Opaque white PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-16546-03 | Apr 29, 2030 | |
TrozinAzithromycin (as dihydrate) | 250 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's); Alu/PVC Blister Pack x 10's (Box of 100's) | Rx | Mercury Laboratories Ltd.India | Phil. Pharmawealth Inc. | DR-XY42867 | Oct 24, 2028 | |
TrozinAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 2's (Box of 100's); Alu/PVC Blister Pack x 3's (Box of 3's) | Rx | Mercury Laboratories Ltd.India | Phil Pharmawealth, Inc. | DR-XY38718 | Nov 4, 2030 | |
UnbrandedAzithromycin (as Dihydrate) | 200 mg/5 mL Powder for SuspensionHDPE White Plastic Bottle with measuring spoon x 15 mL (Box of 1's) | Rx | Hizon Laboratories, Inc.Philippines | — | DRP-6837 | Jul 11, 2029 | |
UnbrandedAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 6’s (Box of 24’s) | Rx | Hizon Laboratories, Inc.Rizal | Dyna Drug Corporation | DRP-3549-08 | Sep 16, 2036 | |
ValzithAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's & 30's); Alu/PVC Blister Pack x 3's per Box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Curasave PharmaImporter: Pharmakon Biotec Inc. | DRP-5403-02 | Jul 23, 2029 | |
VistromycinAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension32 mL Capacity (15 mL net content) amber glass bottle with silver-colored ROPP aluminum cap and 10 mL capacity transparent PP measuring cup (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Vispomed CorporationImporter: Aglobal Care, Inc. | DRP-13507-01 | Mar 2, 2028 | |
WiltrozinAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 6's (Box of 24's); Aluminum Foil Strip x 3's (Box of 3's) | Rx | Hizon Laboratories, Inc.Antipolo City | New Willore Pharma Corp. | DRP-3549 | Sep 16, 2031 | |
XitroAzithromycin (as monohydrate) | 200 mg/5 mL SuspensionAmber Glass Bottle x 15 mL with 5 mL Transparent LDPE Measuring Cup (Box of 1’s); Amber Glass Bottle x 30 mL with 10 mL Transparent LDPE Measuring Cup (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Aisec Pharma CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3431-02 | Dec 7, 2029 | |
Xitro 500Azithromycin | 500 mg Film-Coated TabletPVC/Alu Blister Pack x 3’s Box of 3’s | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Aisec Farma CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3204-09 | Sep 1, 2029 | |
XoraAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's per box x 10’s (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Alkem Laboratories CorporationImporter: Pharmakon Biotec Inc. | DRP-5403-17 | Jul 23, 2029 | |
Xythro 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 6’s (Box of 24’s) | Rx | Hizon Laboratories, Inc.Rizal | Basic Pharmaceutical Corporation | DRP-3549-03 | Sep 16, 2031 | |
Z-MycinAzithromycin (as monohydrate) | 500 mg Film-Coated TabletAlu/White PVC Blister Pack x 3's (Box of 3's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DRP-7475 | Apr 21, 2030 | |
ZalimedAzithromycin (as dihydrate) | 500 mg TabletRed/PVC Alu Blister Pack x 3's (Box of 3's) | Rx | Saga Lifesciences LimitedIndia | Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals | DRP-7320-01 | Oct 8, 2029 | |
ZapzoryxAzithromycin (as monohydrate) | 200 mg/5 mL SuspensionAmber Glass Bottle x 15 mL with 5 mL Transparent LDPE Measuring Cup Box of 1’s; Amber Glass Bottle x 30 mL with 10 mL Transparent LDPE Measuring Cup Box of 1’s | Rx | Akums Drugs & Pharmaceuticals Ltd.India | AJ Research & Pharma Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3431-04 | Dec 7, 2029 | |
ZarocinAzithromycin (as dihydrate) | 500 mg CapsuleAlu/Clear PVC Blister Pack x 3's (Box of 1's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-7914-01 | Feb 15, 2027 | |
ZathrimycinAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 12's and 100's) | Rx | Interphil Laboratories, Inc.Philippines | Lewison Pharmaceutical Corporation | DRP-4391-02 | Apr 29, 2028 | |
ZebazithAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu-PVC Blister Pack x 3's (Box of 3's) | Rx | AMN Life Pvt. Ltd.India | Zebe TradingImporter: Medinova Pharmaceutical Inc. | DRP-12544-03 | Aug 31, 2027 | |
ZeepovitAzithromycin (as dihydrate) | 200 mg/5mL Powder for Oral Suspension15 mL (net content) white HDPE bottle with white opaque child-resistant PP cap and plastic measuring opaque cup (Box of 1's) | Rx | Stallion Laboratories Pvt. LtdIndia | Ambica International Corporation | DRP-16246 | Jan 9, 2030 | |
ZenithAzithromycin (as monohydrate) | 200 mg/5 mL Powder for Suspension60 mL HDPE Plastic Bottle with plastic oral syringe 10 mL (Box of 1's) | Rx | Sandoz S.R.L.Romania | Unilab, Inc.Importer: Sandoz Philippines Corporation | DRP-1879-01 | Nov 27, 2028 | |
ZenithAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC PVDC Blister Pack x 3's (Box of 3's) | Rx | Ind-Swift LimitedIndia | UNILAB, Inc.Importer: Ritemed Phils., Inc. | DRP-8453-01 | Dec 19, 2029 | |
Zenith ODAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral SuspensionHDPE bottle x 15 mL and 30 mL (Box of 1's) | Rx | Zim Laboratories LimitedIndia | UNILAB, Inc. | DRP-12477 | Aug 17, 2027 | |
ZentaraAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu-PVC/PVdC Blister Pack x 3 Tablets (Box of 3 tablets) | Rx | Zim Laboratories LimitedIndia | New Seammed Inc.Importer: Medinova Pharmaceutical Inc. | DRP-8289-01 | Aug 5, 2027 | |
ZentrocinAzithromycin (as dihydrate) | 200 mg / 5 mL Powder for Suspension15 mL and 30 mL HDPE White Colored Plastic Bottle with Pilfer Proof Child Resistant Bottle Cap | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Kodapharm Med Corp.Importer: Accesspoint International Trading Inc. | DRP-5051-05 | Jun 10, 2028 | |
ZenydAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu-Alu Blister Pack x 3's (Box of 3's; Box of 9's and Box of 30's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-12533-02 | Aug 30, 2027 | |
ZetrocynAzithromycin | 500 mg TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-16546 | Apr 29, 2030 | |
ZikantAzithromycin (as dihydrate) | 200 mg/5 mL Powder For Oral Suspension32 mL capacity (15 mL net content) amber glass bottle with silver-colored ROPP aluminum cap and 10 mL capacity transparent PP measuring cup (box x of 1's) | Rx | S Kant Healthcare LimitedIndia | Aglobal Care, Inc. | DRP-13507 | Mar 2, 2028 | |
ZirocinoAzithromycin (as dihydrate) | 500 mg Powder for Injection (I.V.)20 mL capacity USP Type I clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with plastic flip-off cap (box of 1's) | Rx | Sanjar Pharma LLPIndia | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-15522 | Jul 31, 2029 | |
Zit-OdAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3‘s (Box of 3’s) | Rx | Zim Laboratories Ltd.India | Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.) | DRP-2170 | Mar 2, 2031 | |
ZitharixAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3 's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Altor Pharmaceutical Product DistributionImporter: Greencore Pharma Inc. | DRP-8640-11 | Feb 9, 2031 | |
ZithmacAzithromycin (as dihydrate) | 500mg Film-coated TabletAlu/PVC Blister Pack x 3's (Box of 1's) | Rx | Zim Laboratories LimitedIndia | I.E. Medica, Inc. | DRP-9486 | Aug 16, 2030 | |
ZithranAzithromycin (as Monohydrate) | 500 mg Film-Coated TabletAlu/White PVC Blister Pack x 3's (Box of 3's) | Rx | Lloyd Laboratories, Inc.Philippines | Aldril Pharmaceuticals, Inc.Trader: Randril Internation Co., Inc. | DRP-7474 | Mar 8, 2031 | |
ZithrixAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 3’s (Box of 3’s) | Rx | Hizon Laboratories, Inc.Rizal | MG Prime Pharmaceutical, Inc. | DRP-3549-07 | Sep 16, 2031 | |
ZithroaceAzithromycin (as dihydrate) | 500mg Film-Coated TabletAlu/PVC Blister Pack x 3’s (Box of 3’s and 30's) | Rx | Sunrise International Labs LimitedIndia | Genace Pharma DistributorImporter: Despina Pharma Inc. | DRP-15769-02 | Sep 12, 2029 | |
ZithrobbasAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 4's (Box of 4's and 20's) | Rx | Harmann Pharmaceutical Laboratories (PVT) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9320 | Sep 11, 2029 | |
Zithrocare 200Azithromycin (as Dihydrate) | 200 mg / 5 mL Oral SuspensionAmber Glass Bottle x 15 mL and 60 mL (Box of 1's) | Rx | Meyer Organics Pvt. Ltd.India | Khriz Pharma Trading, Inc. | DRP-18033 | Apr 11, 2031 | |
Zithrocare 200Azithromycin (as Dihydrate) | 200 mg/5 mL Oral SuspensionAmber Glass Bottle x 15 mL and 60 mL (Box of 1's) | Rx | Meyer Organics Pvt. Ltd.India | Khriz Pharma Trading, Inc. | DR-XY45249 | Apr 11, 2031 | |
Zithrocare 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu-Clear PVC Blister pack x 3's (Box of 3's); Alu-Clear PVC Blister pack x 2's (Box of 2's) | Rx | Meyer Organics Pvt. Ltd.India | Khriz Pharma Trading Inc.Trader: Meyer Organics Pvt. Ltd. | DR-XY41914 | Apr 4, 2028 | |
ZithrocinAzithromycin (as dihydrate) | 500 mg TabletAluminum Foil Strip x 3’s (Box of 3’s) | Rx | Hizon Laboratories, Inc.Philippines | Trader: PNSV ASIA CORPORATION | DR-XY34686 | Jul 2, 2028 | |
ZithrokidAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral Suspension32 mL-capacity Amber glass bottle with aluminum cap x 15 mL-net content (Box of 1's); 60 mL-capacity Amber glass bottle with aluminum cap x 30 mL-net content (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Legend Pharma Corp.Importer: Triple Tact Import & Export Corp. | DRP-14138-04 | Jun 30, 2028 | |
ZithrolAzithromycin | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-11929 | May 26, 2037 | |
ZithrolabAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister pack x 3’s (Box of 3’s & 6’s); Alu/Alu blister pack x 10’s (Box of 10’s) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Labmate Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-10994-01 | Dec 31, 2026 | |
ZithrolabAzithromycin (as dihydrate) | 500 mg Lyophilized Powder for IV InfusionUSP Type I Glass Vial x 10mL + Clear Ampoule x 5mL Diluent Box of 1's | Rx | Gufic Biosciences Ltd.India | Labmate Pharma Inc.Importer: SRS Life Sciences Inc. | DRP-4213-01 | Dec 6, 2026 | |
ZithromarAzithromycin | 500 mg TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical And Pharma Inc. | DRP-16546-01 | Apr 29, 2030 | |
ZithromaxAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Oral SuspensionHDPE Bottle with PP Cap and double ended measuring spoon x 15 mL and 22.5 mL (Box of 1's) | Rx | Haupt Pharma Latina S.r.1Italy | Pfizer, Inc. | DRP-3367 | Jun 1, 2027 | |
ZithromaxAzithromycin (as dihydrate) | 250 mg Film-Coated TabletWhite opaque PVC/Alu Blister Pack x 3’s (Box of 6’s) | Rx | Viatris Pharmaceuticals LLCUSA | Importer: Pfizer, Inc. | DRP-8703 | Feb 7, 2030 | |
ZithromaxAzithromycin (as dihydrate) | 500 mg Film-Coated TabletWhite opaque PVC/Alu Blister Pack x 3’s Box of 3’s | Rx | Viatris Pharmaceuticals LLCUSA | Importer: Pfizer, Inc. | DRP-8702 | Feb 7, 2030 | |
ZithromaxAzithromycin (As Dihydrate) | 500 mg Powder For I.V. InfusionType I Flint Glass Vial x 1's (Box of 1's) | Rx | Pharmacia and Upjohn Company LLCU.S.A | Importer: Pfizer Inc. | DRP-3378 | May 12, 2027 | |
ZithrominAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/PVDC Blister Pack x 3's (Box of 3's) | Rx | The ACME Laboratories LimitedBangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-3637-02 | Sep 29, 2031 | |
ZithronavAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu-PVC/PVdC Blister Pack x 3 tablets (Box of 3's) | Rx | Zim Laboratories LimitedIndia | JNC Pharmaceuticals CorporationImporter: Medinova Pharmaceutical, Inc. | DRP-8289-05 | Aug 5, 2027 | |
Zithronon 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 30's) | Rx | Interphil Laboratories, Inc.Philippines | Trianon International Inc. | DRP-4391-07 | Apr 29, 2028 | |
Zithropen-200Azithromycin (as Dihydrate) | 200 mg / 5 mL Oral SuspensionAmber Glass Bottle x 15 mL and 60 mL (Box of 1's) | Rx | Meyer Organics Pvt. Ltd.India | A. Pendragon International Distribution OpcImporter: Khriz Pharma Trading, Inc. | DRP-18033-01 | Apr 11, 2031 | |
ZithrophilAzithromycin (as dihydrate) | 500 mg CapsuleAlu/Clear PVC Blister Pack x 3's (Box of 3's); Alu/Clear PVC Blister Pack x 4's (Box of 4's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-7914-05 | Feb 15, 2027 | |
ZithroquestAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 4's (Box of 4's and 20's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Health-Quest Pharma and Medical Supplies TradingImporter: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9320-05 | Sep 11, 2029 | |
ZithrorichAzithromycin (as dihydrate) | 200 mg / 5 mL Powder for Oral Suspension32 mL capacity (15 mL net content) amber glass bottle with silver-colored ROPP aluminum cap and 10 mL capacity transparent PP measuring cup (Box of 1’s) | Rx | S Kant Healthcare LimitedIndia | Medirich Pharma Distribution Corp.Importer: Aglobal Care, Inc. | DRP-13507-05 | Mar 2, 2028 | |
ZithrotechAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's per box x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | One Technodrug Life Sciences Inc.Importer: Pharmakon Biotec Inc. | DRP-5403-20 | Jul 23, 2029 | |
ZithrovateAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu-PVC/PVdC blister pack x 3 tablets (Box of 3 tablets) | Rx | Zim Laboratories LimitedIndia | K Pharma Medical Corp.Importer: Medinova Pharmaceutical Inc. | DRP-8289-04 | Aug 5, 2027 | |
ZithroveeAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Euro-Care Products PhilippinesImporter: Greencore Pharma Inc. | DRP-8640-01 | Feb 15, 2031 | |
ZithrovicAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC blister pack of 3's packed in monocarton (Box of 10's in monocarton) | Rx | Theon Pharmaceuticals LimitedIndia | Grovic Pharma Inc.Importer: Greencore Pharma Inc. | DRP-8640-13 | Jan 22, 2030 | |
ZithroxAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-4614 | May 6, 2027 | |
ZithroxAzithromycin (as dihydrate) | 500 mg Lyophilized Powder For IV Injection10 mL-Capacity Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Aluminum Flip-Off Cap individually packed in a Box (Box of 10's) | Rx | Hainan Brilliant Pharmaceutical Co., Ltd.China | Philgen Pharmaceuticals Inc. | DRP-13667 | Mar 27, 2028 | |
ZithroxinAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 4's (Box of 4's); Alu/Alu Blister Pack x 4's (Box of 20's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Exa Life Care Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9320-04 | Sep 11, 2029 | |
ZithroxinAzithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 4's (Box of 4's and 20's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Exa Life Care Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9320-07 | Sep 11, 2029 | |
ZithxineAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 3's (Box of 3's) | Rx | XL Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4885-01 | Nov 4, 2028 | |
ZithzynAzithromycin (As Dihydrate) | 500 mg Film-Coated TabletAlu-PVC blister pack x 3’s (Box of 3’s) | Rx | UNI MEDICOLABSIndia | Greencore Pharma Inc. | DRP-18969 | Oct 8, 2031 | |
ZitrovexAzithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Vee Excel Drugs & Pharmaceuticals Private LimitedIndia | Aglobal Care, Inc. | DRP-17403 | Dec 11, 2030 | |
Ztab 500Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's per Box x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Sigmamatic Co. Inc.Importer: Pharmakon Biotec Inc. | DRP-5403-19 | Jul 23, 2029 | |
Zthrosur-500Azithromycin (as Dihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 2's in monocarton (Box of 10 monocartons) and Alu/Alu Blister Pack x 3's in monocarton (Box of 10 monocartons) | Rx | Theon Pharmaceuticals Ltd.India | Pharma-Surrey International, Inc. | DRP-10619 | Dec 7, 2026 | |
ZyhexAzithromycin (as dihydrate) | 500 mg TabletRed/PVC Alu Blister Pack x 3's (Box of 3's) | Rx | Saga Lifesciences LimitedIndia | Hexagon Pharmaceuticals | DRP-7320 | Oct 8, 2029 | |
ZymaxAzithromycin (as Dihydrate) | 200 mg/5 mL Powder for SuspensionAmber Bottle of 15 mL with 1.2 mL dropper (Box of 1's); Amber Bottle of 35 mL with 5 mL plastic measuring spoon (Box of 1's) | Rx | Biopharma Laboratories LimitedBangladesh | Importer: JF Draf Pharmaceuticals Corporation | DRP-5134 | Feb 13, 2029 | |
ZymaxAzithromycin (As Dihydrate) | 500 mg Film-Coated TabletAlu-Alu Blister Pack x 3's (Box's of 3's and 6's) | Rx | BIOPHARMA LABORATORIES LIMITEDBangladesh | JF DRAF PHARMACEUTICALS CORPORATION | DRP-3075 | Jun 21, 2030 | |
ZyproAzithromycin (as dihydrate) | 200 mg/5 mL Powder for Suspension15 mL and 30 mL HDPE White Colored Plastic Bottle with Pilfer Proof Child Resistant Bottle Cap (Box of 1's) | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Prebiotech Advanced Pharma Inc.Importer: Accesspoint International Trading Inc. | DRP-5051-06 | Jun 10, 2028 | |
ZytactAzithromycin (as dihydrate) | 200 mg / 5 mL Oral Suspension32 mL-capacity Amber glass bottle with aluminum cap x 15 mL-net content (Box of 1's) | Rx | S Kant Healthcare LimitedIndia | Triple Tact Import & Export Corp. | DRP-14138 | Jun 30, 2028 | |
(no brand name)Azithromycin (as dihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's (Box of 3's) | Rx | Centurion Laboratories Pvt. Ltd.India | Watsons Personal Care Stores (Philippines), Inc.Importer: Philgen Pharmaceuticals Inc. | DRP 4614-01 | May 6, 2027 | |
(no brand name)Azithromycin (as dihtdrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 3's | Rx | Centurion Laboratories Pvt. Ltd.India | Â TGP Pharma Inc.Importer: Â Philgen Pharmaceuticals Inc. | DRP 4614-02 | May 6, 2027 | |
(no brand name)Azithromycin (as dihydrate) | 500 mg Lyophilized Powder Injection (IV/IM)Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | Medethix, Inc. | DRP-16742 | Jul 4, 2030 | |
(no brand name)Azithromycin | 500 mg Lyophilized Solution for IV Infusion | Rx | Naprod Lifesciences Pvt. Ltd.India | Ritemed Phils., Inc. | DRP-17595 | Feb 6, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS ZITHROMAX 250 mg tablets are supplied as pink modified capsular shaped, engraved, film-coated tablets containing azithromycin dihydrate equivalent to 250 mg of azithromycin. ZITHROMAX 250 mg tablets are engraved with "PFIZER" on one side and "306" on the other, or "Pfizer" on one side and "ZTM 250" on the other.
ZITHROMAX 500 mg tablets are supplied as pink modified capsular shaped, engraved, film-coated tablets containing azithromycin dihydrate equivalent to 500 mg of azithromycin. ZITHROMAX 500 mg tablets are engraved with "Pfizer" on one side and "ZTM500" on the other. ZITHROMAX for oral suspension after constitution contains a flavored suspension.
ZITHROMAX for oral suspension is supplied to provide 100 mg/5 mL or 200 mg/5 mL suspension in bottles.
- ZITHROMAX tablets 250 mg and 500 mg (3)
- ZITHROMAX for oral suspension 100 mg/5 mL and 200 mg/5 mL (3)
Warnings/Precautions
- • Serious (including fatal) allergic and skin reactions: Discontinue ZITHROMAX if reaction occurs. (5.1)
- • Hepatotoxicity: Severe, and sometimes fatal, hepatotoxicity has been reported. Discontinue ZITHROMAX immediately if signs and symptoms of hepatitis occur. (5.2)
- • Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs. (5.3)
- • Prolongation of QT interval and cases of torsades de pointes have been reported. This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (5.4)
- • Cardiovascular Death: Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. Consider balancing this potential risk with treatment benefits when prescribing ZITHROMAX. (5.5)
- • Clostridioides difficile -Associated Diarrhea: Evaluate patients if diarrhea occurs. (5.6)
- • ZITHROMAX may exacerbate muscle weakness in persons with myasthenia …
5.1 Hypersensitivity
5.1 Hypersensitivity Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported in patients on azithromycin therapy. [see Contraindications (4.1)] Fatalities have been reported. Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported.
Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurred soon thereafter in some patients without further azithromycin exposure. These patients required prolonged periods of observation and symptomatic treatment. The relationship of these episodes to the long tissue half-life of azithromycin and subsequent prolonged exposure to antigen is presently unknown.
If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that allergic symptoms may reappear when symptomatic therapy has been discontinued.
5.2 Hepatotoxicity
5.2 Hepatotoxicity Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur.
5.3 Infantile Hypertrophic Pyloric Stenosis (IHPS)
5.3 Infantile Hypertrophic Pyloric Stenosis (IHPS) Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs.
5.4 QT Prolongation
5.4 QT Prolongation Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen with treatment with macrolides, including azithromycin. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving azithromycin.
Providers should consider the risk of QT prolongation which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including:
- patients with known prolongation of the QT interval, a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure
- patients on drugs known to prolong the QT interval
- patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval.
5.5 Cardiovascular Death
5.5 Cardiovascular Death Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. The five-day cardiovascular mortality observed in these studies ranged from 20 to 400 per million azithromycin treatment courses.
This potential risk was noted to be greater during the first five days of azithromycin use and does not appear to be limited to those patients with preexisting cardiovascular diseases. The data in these observational studies are insufficient to establish or exclude a causal relationship between acute cardiovascular death and azithromycin use.
Consider balancing this potential risk with treatment benefits when prescribing ZITHROMAX.
5.6 Clostridioides difficile- Associated Diarrhea
5.6 Clostridioides difficile- Associated Diarrhea Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including ZITHROMAX, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use.
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
5.7 Exacerbation of Myasthenia Gravis
5.7 Exacerbation of Myasthenia Gravis Exacerbation of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy.
5.8 Risk of Antibacterial Resistance in Sexually Transmitted Infections
5.8 Risk of Antibacterial Resistance in Sexually Transmitted Infections ZITHROMAX, at the recommended dose, should not be relied upon to treat syphilis. Antibacterial agents used to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis.
Appropriate antibacterial therapy and follow-up tests for these diseases should be initiated if infection is confirmed.
5.9 Development of Drug-Resistant Bacteria Prescribing
5.9 Development of Drug-Resistant Bacteria Prescribing ZITHROMAX in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Warfarin | Adjust or monitor | May increase coagulation times (label). | Monitor prothrombin time. |
| Nelfinavir | Adjust or monitor | Higher azithromycin levels (label). | No dose change; watch for liver and hearing effects. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewed- • Nelfinavir: Close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. (7.1)
- • Warfarin: Use with azithromycin may increase coagulation times; monitor prothrombin time. (7.2)
7.1 Nelfinavir
7.1 Nelfinavir Co-administration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. [see Adverse Reactions (6)]
7.2 Warfarin
7.2 Warfarin Spontaneous postmarketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral anticoagulants such as warfarin, although the prothrombin time was not affected in the dedicated drug interaction study with azithromycin and warfarin. Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly.
7.3 Potential Drug-Drug Interaction with Macrolides
7.3 Potential Drug-Drug Interaction with Macrolides Interactions with digoxin, colchicine or phenytoin have not been reported in clinical trials with azithromycin. No specific drug interaction studies have been performed to evaluate potential drug-drug interaction. However, drug interactions have been observed with other macrolide products.
Until further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used with azithromycin careful monitoring of patients is advised.
Adverse reactions
Common
- Diarrhea (5% to 14%), nausea (3% to 18%)
- Abdominal pain, vomiting
Serious
- Serious allergic and skin reactions
- Hepatotoxicity
- QT prolongation and torsades de pointes
- Infantile hypertrophic pyloric stenosis (neonates)
- Myasthenia gravis exacerbation
- Clostridioides difficile-associated diarrhea
- The following clinically significant adverse reactions are described elsewhere in labeling: • Hypersensitivity [see Warnings and Precautions (5.1)] • Hepatotoxicity [see Warnings and Precautions (5.2)] • Infantile Hypertrophic Pyloric Stenosis (IHPS) [see Warnings and Precautions (5.3)] • QT Prolongation [see Warnings and Precautions (5.4)] • Cardiovascular Death [see Warnings and Precautions (5.5)] • Clostridioides difficile- Associated Diarrhea (CDAD) [see Warnings and Precautions (5.6)] • Exacerbation of Myasthenia Gravis [see Warnings and Precautions (5.7)] Most common adverse reactions are diarrhea (5 to 14%), nausea (3 to 18%), abdominal pain (3 to 7%), or vomiting (2 to 7%). (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, most of the reported side effects were mild to moderate in severity and were reversible upon discontinuation of the drug.
Potentially serious adverse reactions of angioedema and cholestatic jaundice were reported. Approximately 0.7% of the patients (adults and pediatric patients) from the 5-day multiple-dose clinical trials discontinued ZITHROMAX therapy because of treatment-related adverse reactions. In adults given 500 mg/day for 3 days, the discontinuation rate due to treatment-related adverse reactions was 0.6%.
In clinical trials in pediatric patients given 30 mg/kg, either as a single dose or over 3 days, discontinuation from the trials due to treatment-related adverse reactions was approximately 1%. Most of the adverse reactions leading to discontinuation were related to the gastrointestinal tract, e.g., nausea, vomiting, diarrhea, or abdominal pain. [see Clinical Studies (14.2)] Clinical Trials Experience in Adults Multiple-dose regimens: Overall, the most common treatment-related adverse reactions in adult patients receiving multiple-dose regimens of ZITHROMAX were related to the gastrointestinal system with diarrhea/loose stools (4 to 5%), nausea (3%), and abdominal pain (2 to 3%) being the most frequently reported.
No other adverse reactions occurred in patients on the multiple-dose regimens of ZITHROMAX with a frequency greater than 1%. Adverse reactions that occurred with a frequency of 1% or less included the following: Cardiovascular: Palpitations, chest pain. Gastrointestinal: Dyspepsia, flatulence, vomiting, melena, and cholestatic jaundice.
Genitourinary: Monilia, vaginitis, and nephritis. Nervous System: Dizziness, headache, vertigo, and somnolence. General: Fatigue. Allergic: Rash, pruritus, photosensitivity, and angioedema. Single 1-gram dose regimen: Overall, the most common adverse reactions in patients receiving a single-dose regimen of 1 gram of ZITHROMAX were related to the gastrointestinal system and were more frequently reported than in patients receiving the multiple-dose regimen.
Adverse reactions that occurred in patients on the single 1-gram dosing regimen of ZITHROMAX with a frequency of 1% or greater included diarrhea/loose stools (7%), nausea (5%), abdominal pain (5%), vomiting (2%), dyspepsia (1%), and vaginitis (1%). Single 2-gram dose regimen: Overall, the most common adverse reactions in patients receiving a single 2-gram dose of ZITHROMAX were related to the gastrointestinal system.
Adverse reactions that occurred in patients in this study with a frequency of 1% or greater included nausea (18%), diarrhea/loose stools (14%), vomiting (7%), abdominal pain (7%), vaginitis (2%), dyspepsia (1%), and dizziness (1%). The majority of these complaints were mild in nature. Clinical Trials Experience in Pediatric Patients Single and Multiple-dose regimens: The types of adverse reactions in pediatric patients were comparable to those seen in adults, with different incidence rates for the dosage regimens recommended in pediatric patients.
Acute Otitis Media: For the recommended total dosage regimen of 30 mg/kg, the most frequent adverse reactions (≥1%) attributed to treatment were diarrhea, abdominal pain, vomiting, nausea, and rash. [see Dosage and Administration (2) and Clinical Studies (14.2)] The incidence, based on dosing regimen, is described in table 8 below: Table 8. Incidence of Adverse Reactions in Pediatric Patients Treated for Acute Otitis Media Dosage Regimen Diarrhea % Abdominal Pain % Vomiting % Nausea % Rash % 1-day 4.3% 1.4% 4.9% 1.0% 1.0% 3-day 2.6% 1.7% 2.3% 0.4% 0.6% 5-day 1.8% 1.2% 1.1% 0.5% 0.4% Community-Acquired Pneumonia: For the recommended dosage regimen of 10 mg/kg on Day 1 followed by 5 mg/kg on Days 2-5, the most frequent adverse reactions attributed to treatment were diarrhea/loose stools, abdominal pain, vomiting, nausea, and rash.
The incidence is described in table 9 below: Table 9. Incidence of Adverse Reactions in Pediatric Patients Treated for Community-Acquired Pneumonia Dosage Regimen Diarrhea/Loose stools % Abdominal Pain % Vomiting % Nausea % Rash % 5-day 5.8% 1.9% 1.9% 1.9% 1.6% Pharyngitis/Tonsillitis: For the recommended dosage regimen of 12 mg/kg on Days 1-5, the most frequent adverse reactions attributed to treatment were diarrhea, vomiting, abdominal pain, nausea, and headache.
The incidence is described in table 10 below: Table 10. Incidence of Adverse Reactions in Pediatric Patients Treated for Pharyngitis/Tonsillitis Dosage Regimen Diarrhea % Abdominal Pain % Vomiting % Nausea % Rash % Headache % 5-day 5.4% 3.4% 5.6% 1.8% 0.7% 1.1% With any of the treatment regimens, no other adverse reactions occurred in pediatric patients treated with ZITHROMAX with a frequency greater than 1%.
Adverse reactions that occurred with a frequency of 1% or less included the following: Cardiovascular: Chest pain. Gastrointestinal: Dyspepsia, constipation, anorexia, enteritis, flatulence, gastritis, jaundice, loose stools, and oral moniliasis. Hematologic and Lymphatic: Anemia and leukopenia. Nervous System: Headache (otitis media dosage), hyperkinesia, dizziness, agitation, nervousness, and insomnia.
General: Fever, face edema, fatigue, fungal infection, malaise, and pain. Allergic: Rash and allergic reaction. Respiratory: Cough, pharyngitis, pleural effusion, and rhinitis. Skin and Appendages: Eczema, fungal dermatitis, pruritus, sweating, urticaria, and vesiculobullous rash. Special Senses: Conjunctivitis.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of azithromycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Adverse reactions reported with azithromycin during the postmarketing period in adult and/or pediatric patients for which a causal relationship may not be established include: Allergic: Arthralgia, edema, urticaria, and angioedema. Cardiovascular: Arrhythmias including ventricular tachycardia and hypotension. There have been reports of QT prolongation, torsades de pointes, and cardiovascular death.
Gastrointestinal: Anorexia, constipation, dyspepsia, flatulence, vomiting/diarrhea, pseudomembranous colitis, pancreatitis, oral candidiasis, pyloric stenosis, and reports of tongue discoloration. General: Asthenia, paresthesia, fatigue, malaise, and anaphylaxis. Genitourinary: Interstitial nephritis and acute renal failure and vaginitis.
Hematopoietic: Thrombocytopenia. Liver/Biliary: Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure. [see Warnings and Precautions (5.2)] Nervous System: Convulsions, dizziness/vertigo, headache, somnolence, hyperactivity, nervousness, agitation, and syncope. Psychiatric: Aggressive reaction and anxiety.
Skin/Appendages: Pruritus serious skin reactions including erythema multiforme, AGEP, Stevens-Johnson Syndrome, toxic epidermal necrolysis, and DRESS. Special Senses: Hearing disturbances including hearing loss, deafness and/or tinnitus, and reports of taste/smell perversion and/or loss.
6.3 Laboratory Abnormalities Adults
6.3 Laboratory Abnormalities Adults Clinically significant abnormalities (irrespective of drug relationship) occurring during the clinical trials were reported as follows: with an incidence of greater than 1%: decreased hemoglobin, hematocrit, lymphocytes, neutrophils, and blood glucose; elevated serum creatine phosphokinase, potassium, ALT, GGT, AST, BUN, creatinine, blood glucose, platelet count, lymphocytes, neutrophils, and eosinophils; with an incidence of less than 1%: leukopenia, neutropenia, decreased sodium, potassium, platelet count, elevated monocytes, basophils, bicarbonate, serum alkaline phosphatase, bilirubin, LDH, and phosphate. The majority of subjects with elevated serum creatinine also had abnormal values at baseline.
When follow-up was provided, changes in laboratory tests appeared to be reversible. In multiple-dose clinical trials involving more than 5000 patients, four patients discontinued therapy because of treatment-related liver enzyme abnormalities and one because of a renal function abnormality. Pediatric Patients One, Three, and Five-Day Regimens Laboratory data collected from comparative clinical trials employing two 3-day regimens (30 mg/kg or 60 mg/kg in divided doses over 3 days), or two 5-day regimens (30 mg/kg or 60 mg/kg in divided doses over 5 days) were similar for regimens of azithromycin and all comparators combined, with most clinically significant laboratory abnormalities occurring at incidences of 1–5%.
Laboratory data for patients receiving 30 mg/kg as a single dose were collected in one single center trial. In that trial, an absolute neutrophil count between 500–1500 cells/mm 3 was observed in 10/64 patients receiving 30 mg/kg as a single dose, 9/62 patients receiving 30 mg/kg given over 3 days, and 8/63 comparator patients.
No patient had an absolute neutrophil count <500 cells/mm 3. In multiple-dose clinical trials involving approximately 4700 pediatric patients, no patients discontinued therapy because of treatment-related laboratory abnormalities.
Adverse reaction frequency tables (US label) US FDA label
| Table 8. Incidence of Adverse Reactions in Pediatric Patients Treated for Acute Otitis Media | |||||
|---|---|---|---|---|---|
| Dosage Regimen | Diarrhea % | Abdominal Pain % | Vomiting % | Nausea % | Rash % |
| 1-day | 4.3% | 1.4% | 4.9% | 1.0% | 1.0% |
| 3-day | 2.6% | 1.7% | 2.3% | 0.4% | 0.6% |
| 5-day | 1.8% | 1.2% | 1.1% | 0.5% | 0.4% |
| Table 9. Incidence of Adverse Reactions in Pediatric Patients Treated for Community-Acquired Pneumonia | |||||
|---|---|---|---|---|---|
| Dosage Regimen | Diarrhea/Loose stools % | Abdominal Pain % | Vomiting % | Nausea % | Rash % |
| 5-day | 5.8% | 1.9% | 1.9% | 1.9% | 1.6% |
| Table 10. Incidence of Adverse Reactions in Pediatric Patients Treated for Pharyngitis/Tonsillitis | ||||||
|---|---|---|---|---|---|---|
| Dosage Regimen | Diarrhea % | Abdominal Pain % | Vomiting % | Nausea % | Rash % | Headache % |
| 5-day | 5.4% | 3.4% | 5.6% | 1.8% | 0.7% | 1.1% |
Monitoring parameters
- QT interval in patients at risk (QT prolongation, low potassium or magnesium, bradycardia, class IA or III antiarrhythmics); liver tests if symptoms; INR with warfarin (label). Kidney
- QT and electrolytes when at risk
- INR with warfarin
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from published literature and postmarketing experience over several decades with azithromycin use in pregnant women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). Developmental toxicity studies with azithromycin in rats, mice, and rabbits showed no drug-induced fetal malformations at doses up to 4, 2, and 2 times, respectively, an adult human daily dose of 500 mg based on body surface area.
Decreased viability and delayed development were observed in the offspring of pregnant rats administered azithromycin from day 6 of pregnancy through weaning at a dose equivalent to 4 times an adult human daily dose of 500 mg based on body surface area (see Data). The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data Available data from published observational studies, case series, and case reports over several decades do not suggest an increased risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with azithromycin use in pregnant women.
Limitations of these data include the lack of randomization and inability to control for confounders such as underlying maternal disease and maternal use of concomitant medications. Animal Data Azithromycin administered during the period of organogenesis did not cause fetal malformations in rats and mice at oral doses up to 200 mg/kg/day (moderately maternally toxic).
Based on body surface area, this dose is approximately 4 (rats) and 2 (mice) times an adult human daily dose of 500 mg. In rabbits administered azithromycin at oral doses of 10, 20, and 40 mg/kg/day during organogenesis, reduced maternal body weight and food consumption were observed in all groups; no evidence of fetotoxicity or teratogenicity was observed at these doses, the highest of which is estimated to be 2 times an adult human daily dose of 500 mg based on body surface area.
In a pre- and postnatal development study, azithromycin was administered orally to pregnant rats from day 6 of pregnancy until weaning at doses of 50 or 200 mg/kg/day. Maternal toxicity (reduced food consumption and body weight gain; increased stress at parturition) was observed at the higher dose. Effects in the offspring were noted at 200 mg/kg/day during the postnatal development period (decreased viability, delayed developmental landmarks).
These effects were not observed in a pre- and postnatal rat study when up to 200 mg/kg/day of azithromycin was given orally beginning on day 15 of pregnancy until weaning.
Mechanism of action
12.1 Mechanism of Action Azithromycin is a macrolide antibacterial drug. [see Microbiology (12.4)]
Mechanism of Action Azithromycin acts by binding to the 23S rRNA of the 50S ribosomal subunit of susceptible microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal subunit. Resistance Azithromycin demonstrates cross resistance with erythromycin. The most frequently encountered mechanism of resistance to azithromycin is modification of the 23S rRNA target, most often by methylation.
Ribosomal modifications can determine cross resistance to other macrolides, lincosamides, and streptogramin B (MLS B phenotype). Antimicrobial Activity Azithromycin has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections. [see Indications and Usage (1)] Gram-Positive Bacteria Staphylococcus aureus Streptococcus agalactiae Streptococcus pneumoniae Streptococcus pyogenes Gram-Negative Bacteria Haemophilus ducreyi Haemophilus influenzae Moraxella catarrhalis Neisseria gonorrhoeae Other Bacteria Chlamydophila pneumoniae Chlamydia trachomatis Mycoplasma pneumoniae The following in vitro data are available, but their clinical significance is unknown.
At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for azithromycin against isolates of similar genus or organism group. However, the efficacy of azithromycin in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.
Gram-Positive Bacteria Beta-hemolytic streptococci (Groups C, F, G) Viridans group streptococci Gram-Negative Bacteria Bordetella pertussis Legionella pneumophila Anaerobic Bacteria Prevotella bivia Peptostreptococcus species Other Bacteria Ureaplasma urealyticum
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Based on animal models of infection, the antibacterial activity of azithromycin appears to correlate with the ratio of area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC) for certain pathogens (S. pneumoniae and S. aureus). The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has not been elucidated in clinical trials with azithromycin.
Cardiac Electrophysiology QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 116 healthy subjects who received either chloroquine (1000 mg) alone or in combination with oral azithromycin (500 mg, 1000 mg, and 1500 mg once daily). Co-administration of azithromycin increased the QTc interval in a dose- and concentration- dependent manner.
In comparison to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QTcF were 5 (10) ms, 7 (12) ms and 9 (14) ms with the co-administration of 500 mg, 1000 mg and 1500 mg azithromycin, respectively.
Pharmacokinetics
Key PK parameters
| Bioavailability | About 38% (250 mg capsules) |
|---|---|
| Half-life | About 68 to 72 hours (terminal) |
| Half-life in kidney failure (ESKD) kidney | AUC +35% at GFR below 10 (label) |
| Protein binding | 7% to 51% (falls as concentration rises) |
| Metabolism (CYP, transporters) | Biliary excretion, mostly unchanged |
| Renal excretion kidney | About 6% unchanged in urine over a week |
| Dialyzability kidney | Not stated |
Excretion Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
The prolonged terminal half-life is thought to be due to extensive uptake and subsequent release of drug from tissues.
Biliary excretion of azithromycin, predominantly as unchanged drug, is a major route of elimination.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Following oral administration of a single 500 mg dose (two 250 mg tablets) to 36 fasted healthy male volunteers, the mean (SD) pharmacokinetic parameters were AUC 0–72 =4.3 (1.2) mcg∙hr/mL; C max =0.5 (0.2) mcg/mL; T max =2.2 (0.9) hours. Two azithromycin 250 mg tablets are bioequivalent to a single 500 mg tablet.
In a two-way crossover study, 12 adult healthy volunteers (6 males, 6 females) received 1500 mg of azithromycin administered in single daily doses over either 5 days (two 250 mg tablets on day 1, followed by one 250 mg tablet on days 2–5) or 3 days (500 mg per day for days 1–3). Due to limited serum samples on day 2 (3-day regimen) and days 2–4 (5-day regimen), the serum concentration-time profile of each subject was fit to a 3-compartment model and the AUC 0–∞ for the fitted concentration profile was comparable between the 5-day and 3-day regimens.
Table 11. Pharmacokinetic Parameters for Adult Patients Receiving a 3‑Day and 5‑Day Oral Regimen 3-Day Regimen 5-Day Regimen Pharmacokinetic Parameter [mean (SD)] Day 1 Day 3 Day 1 Day 5 C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
In a two-way crossover study in which 12 healthy subjects received a single 500 mg dose of azithromycin (two 250 mg tablets) with or without a high fat meal, food was shown to increase C max by 23% but had no effect on AUC. When azithromycin oral suspension was administered with food to 28 adult healthy male subjects, C max increased by 56% and AUC was unchanged.
Distribution The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 mcg/mL to 7% at 2 mcg/mL. The antibacterial activity of azithromycin is pH related and appears to be reduced with decreasing pH, However, the extensive distribution of drug to tissues may be relevant to clinical activity.
Azithromycin has been shown to penetrate into human tissues, including skin, lung, tonsil, and cervix. Extensive tissue distribution was confirmed by examination of additional tissues and fluids (bone, ejaculum, prostate, ovary, uterus, salpinx, stomach, liver, and gallbladder). As there are no data from adequate and well-controlled studies of azithromycin treatment of infections in these additional body sites, the clinical significance of these tissue concentration data is unknown.
Following a regimen of 500 mg on the first day and 250 mg daily for 4 days, very low concentrations were noted in cerebrospinal fluid (less than 0.01 mcg/mL) in the presence of noninflamed meninges. Elimination Metabolism In vitro and in vivo studies to assess the metabolism of azithromycin have not been performed. Excretion Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr.
The prolonged terminal half-life is thought to be due to extensive uptake and subsequent release of drug from tissues. Biliary excretion of azithromycin, predominantly as unchanged drug, is a major route of elimination. Over the course of a week, approximately 6% of the administered dose appears as unchanged drug in urine.
Specific Populations Patients with Renal Impairment Azithromycin pharmacokinetics was investigated in 42 adults (21 to 85 years of age) with varying degrees of renal impairment. Following the oral administration of a single 1.0 g dose of azithromycin (4 × 250 mg capsules), mean C max and AUC 0–120 increased by 5.1% and 4.2%, respectively, in subjects with GFR 10 to 80 mL/min compared to subjects with GFR >80 mL/min.
The mean C max and AUC 0–120 increased 61% and 35%, respectively, in subjects with GFR <10 mL/min compared to subjects with GFR >80 mL/min. Patients with Hepatic Impairment The pharmacokinetics of azithromycin in subjects with hepatic impairment has not been established. Male and Female Patients There are no significant differences in the disposition of azithromycin between male and female subjects.
No dosage adjustment is recommended based on gender. Geriatric Patients Pharmacokinetic parameters in older volunteers (65 to 85 years old) were similar to those in young adults (18 to 40 years old) for the 5-day therapeutic regimen. Dosage adjustment does not appear to be necessary for older patients with normal renal and hepatic function receiving treatment with this dosage regimen. [see Geriatric Use (8.5)] Pediatric Patients In two clinical studies, azithromycin for oral suspension was dosed at 10 mg/kg on day 1, followed by 5 mg/kg on days 2 through 5 in two groups of pediatric patients (aged 1–5 years and 5–15 years, respectively).
The mean pharmacokinetic parameters on day 5 were C max =0.216 mcg/mL, T max =1.9 hr, and AUC 0–24 =1.822 mcg∙hr/mL for the 1 to 5-year-old group and were C max =0.383 mcg/mL, T max =2.4 hr, and AUC 0–24 =3.109 mcg∙hr/mL for the 5 to 15-year-old group. In another study, 33 pediatric patients received doses of 12 mg/kg/day (maximum daily dose 500 mg) for 5 days, of whom 31 patients were evaluated for azithromycin pharmacokinetics following a low fat breakfast.
In this study, azithromycin concentrations were determined over a 24 hr period following the last daily dose. Patients weighing above 41.7 kg received the maximum adult daily dose of 500 mg. Seventeen patients (weighing 41.7 kg or less) received a total dose of 60 mg/kg. The table 12 shows pharmacokinetic data in the subset of pediatric patients who received a total dose of 60 mg/kg.
Table 12. Pharmacokinetic Parameters for Pediatric Patients Receiving 12 mg/kg/day (5-day Regimen) Pharmacokinetic Parameter [mean (SD)] 5-Day Regimen (12 mg/kg for 5 days) N 17 C max (mcg/mL) 0.5 (0.4) T max (hr) 2.2 (0.8) AUC 0–24 (mcg∙hr/mL) 3.9 (1.9) Single dose pharmacokinetics of azithromycin in pediatric patients given doses of 30 mg/kg have not been studied. [see Dosage and Administration (2)] Drug Interaction Studies Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered.
The effects of co-administration of azithromycin on the pharmacokinetics of other drugs are shown in Table 13 and the effects of other drugs on the pharmacokinetics of azithromycin are shown in Table 14. Co-administration of azithromycin at therapeutic doses had a modest effect on the pharmacokinetics of the drugs listed in Table 13.
No dosage adjustment of drugs listed in Table 13 is recommended when co-administered with azithromycin. Co-administration of azithromycin with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin. Nelfinavir significantly increased the C max and AUC of azithromycin. No dosage adjustment of azithromycin is recommended when administered with drugs listed in Table 14. [see Drug Interactions (7.3)] Table 13.
Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Azithromycin Co-administered Drug Dose of Co-administered Drug Dose of Azithromycin n Ratio (with/without azithromycin) of Co-administered Drug Pharmacokinetic Parameters (90% CI); No Effect = 1.00 Mean C max Mean AUC Atorvastatin 10 mg/day for 8 days 500 mg/day orally on days 6–8 12 0.83 (0.63 to 1.08) 1.01 (0.81 to 1.25) Carbamazepine 200 mg/day for 2 days, then 200 mg twice a day for 18 days 500 mg/day orally for days 16–18 7 0.97 (0.88 to 1.06) 0.96 (0.88 to 1.06) Cetirizine 20 mg/day for 11 days 500 mg orally on day 7, then 250 mg/day on days 8–11 14 1.03 (0.93 to 1.14) 1.02 (0.92 to 1.13) Didanosine 200 mg orally twice a day for 21 days 1200 mg/day orally on days 8–21 6 1.44 (0.85 to 2.43) 1.14 (0.83 to 1.57) Efavirenz 400 mg/day for 7 days 600 mg orally on day 7 14 1.04 - 90% Confidence interval not reported 0.95 Fluconazole 200 mg orally single dose 1200 mg orally single dose 18 1.04 (0.98 to 1.11) 1.01 (0.97 to 1.05) Indinavir 800 mg three times a day for 5 days 1200 mg orally on day 5 18 0.96 (0.86 to 1.08) 0.90 (0.81 to 1.00) Midazolam 15 mg orally on day 3 500 mg/day orally for 3 days 12 1.27 (0.89 to 1.81) 1.26 (1.01 to 1.56) Nelfinavir 750 mg three times a day for 11 days 1200 mg orally on day 9 14 0.90 (0.81 to 1.01) 0.85 (0.78 to 0.93) Sildenafil 100 mg on days 1 and 4 500 mg/day orally for 3 days 12 1.16 (0.86 to 1.57) 0.92 (0.75 to 1.12) Theophylline 4 mg/kg IV on days 1, 11, 25 500 mg orally on day 7, 250 mg/day on days 8–11 10 1.19 (1.02 to 1.40) 1.02 (0.86 to 1.22) Theophylline 300 mg orally twice a day for 15 days 500 mg orally on day 6, then 250 mg/day on days 7–10 8 1.09 (0.92 to 1.29) 1.08 (0.89 to 1.31) Triazolam 0.125 mg on day 2 500 mg orally on day 1, then 250 mg/day on day 2 12 1.06 1.02 Trimethoprim/ Sulfamethoxazole 160 mg/800 mg/day orally for 7 days 1200 mg orally on day 7 12 0.85 (0.75 to 0.97)/0.90 (0.78 to 1.03) 0.87 (0.80 to 0.95)/0.96 (0.88 to 1.03) Zidovudine 500 mg/day orally for 21 days 600 mg/day orally for 14 days 5 1.12 (0.42 to 3.02) 0.94 (0.52 to 1.70) Zidovudine 500 mg/day orally for 21 days 1200 mg/day orally for 14 days 4 1.31 (0.43 to 3.97) 1.30 (0.69 to 2.43) Table 14. Drug Interactions: Pharmacokinetic Parameters for Azithromycin in the Presence of Co-administered Drugs. [see Drug Interactions (7)] Co-administered Drug Dose of Co-administered Drug Dose of Azithromycin n Ratio (with/without co-administered drug) of Azithromycin Pharmacokinetic Parameters (90% CI); No Effect = 1.00 Mean C max Mean AUC Efavirenz 400 mg/day for 7 days 600 mg orally on day 7 14 1.22 (1.04 to 1.42) 0.92 - 90% Confidence interval not reported Fluconazole 200 mg orally single dose 1200 mg orally single dose 18 0.82 (0.66 to 1.02) 1.07 (0.94 to 1.22) Nelfinavir 750 mg three times a day for 11 days 1200 mg orally on day 9 14 2.36 (1.77 to 3.15) 2.12 (1.80 to 2.50) Oral Antacids (Aluminum Hydroxide, Magnesium Hydroxide) 1350 mg aluminum hydroxide and 1200 mg of magnesium hydroxide single dose on day 1 or day 8 500 mg orally on day 1 and day 8 10 0.765 0.984
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Azithromycin 200 mg/5 mL, 15 mL Suspension | ₱114.40–₱348.00Reference ₱230.00 | per unit | DPRI procurement range |
| Azithromycin 500 mg Tablet | ₱6.97–₱123.00Reference ₱8.98 | per tablet | DPRI procurement range |
| Azithromycin 500 mg Vial | ₱223.44–₱610.00Reference ₱322.00 | per vial | DPRI procurement range |
| 200 mg/5 mL (as base/dihydrate/monohydrate) powder for suspension in 15 mL | ₱270.00 | per unit | PhilHealth GAMOT fixed fee |
| 200 mg/5 mL (as base/dihydrate/monohydrate) powder for suspension in 60 mL | ₱262.50 | per unit | PhilHealth GAMOT fixed fee |
| 250 mg (as base/dihydrate) capsule | ₱35.00 | per capsule | PhilHealth GAMOT fixed fee |
| 250 mg (as base/dihydrate/monohydrate) tablet | ₱100.00 | per tablet | PhilHealth GAMOT fixed fee |
| 500 mg (as base/dihydrate/monohydrate) tablet | ₱74.25 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Azithromycin |
| PNF listing | Oral: 250 mg capsule (as base*/asdihydrate) |
| PNF listing | Oral: 250 mg and 500 mg tablet (as base*/as dihydrate/as monohydrate)Restrictions: List B: in vivo bioequivalence studies required (PNF code B) |
| PNF listing | Oral: 200 mg/5 mL powder for suspension, 15 mL and 60 mL (as base*/as dihydrate/as monohydrate) |
| PNF listing | Inj.: 500 mg powder, vial (IV infusion) (as base*/as dihydrate) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Zithromax · Pfizer Laboratories Div Pfizer Inc [US FDA-approved label, version 49, July 24, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db52b91e-79f7-4cc1-9564-f2eee8e31c45
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Pfizer Laboratories Div Pfizer Inc. (2026). ZITHROMAX (azithromycin) tablets and oral suspension [Prescribing information; US FDA-approved label, NDA050711, set ID db52b91e-79f7-4cc1-9564-f2eee8e31c45, version effective July 24, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db52b91e-79f7-4cc1-9564-f2eee8e31c45
- Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .

